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Summary 
NF-κB signaling is frequently deregulated in a variety of cancers and is constitutively active in 
estrogen receptor negative breast cancer subtypes. These molecular subtypes of breast cancer 
are associated with poor overall survival. During my PhD work, I focused on mechanisms of 
NF-κB regulation in breast cancer by miRNAs, key regulators of eukaryotic gene expression, 
which bind their target mRNAs via seed sequences and inhibit gene expression at the post 
transcriptional level. In a previous study, miR-30c-2-3p was found to be one of the strongest 
negative regulators of NF-κB signaling in a genome-wide miRNA screen. I uncovered the 
underlying molecular mechanisms by which miR-30c-2-3p regulates NF-κB signaling and cell 
cycle progression in breast cancer by combining in vitro data with publically available breast 
cancer patient datasets. 
 
I could show that miR-30c-2-3p directly targets TRADD, an adaptor protein of the TNFR/NF-
κB signaling pathway as well as the cell cycle protein, CCNE1. Ectopic expression of miR-30c-
2-3p downregulated essential cytokines IL8, IL6 and CXCL1, reduced cell proliferation, and 
invasion in MDA-MB-231 breast cancer cells. RNAi-induced silencing of TRADD 
phenocopied the effects on invasion and cytokine expression also observed with miR-30c-2-3p, 
while inhibition of CCNE1 phenocopied the effects of the miRNA on cell proliferation. The 
tumor suppressive role of miR-30c-2-3p was confirmed in a cohort of 781 breast tumors with 
matched mRNA and miRNA expression data where higher expression of miR-30c-2-3p was 
associated with better survival. Furthermore an anticorrelation with expression of target genes 
and miR-30c-2-3p was seen in these breast cancer patients. These findings are important in the 
context of breast cancer where NF-κB signaling has been implicated to play a role in tumor 
initiation, progression, metastasis and resistance to chemotherapy.  
 
During my thesis work I could establish that miR-30c-2-3p negatively regulates both NF-κB 
signaling and cell cycle progression, that are two important signaling pathways frequently 
deregulated in breast cancer. As a result, miR-30c-2-3p directly effects several hallmarks of 
cancer cells, i.e., proliferation, expression of inflammatory cytokines as well as invasion, and 
can be potentially used for therapeutic intervention in miRNA based cancer therapy. 
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Zusammenfassung 
Der NF-κB Signalweg ist bei einer Vielzahl von Krebsentitäten dereguliert und konstitutiv bei 
Brustkrebs Subtypen aktiviert, die durch einen negativen Estrogen-Rezeptor Status 
gekennzeichnet sind. Diese molekularen Subtypen des Brustkrebs sind mit einer schlechten 
Überlebenswahrscheinlichkeit assoziiert. Der Fokus meiner Doktorarbeit lag auf den 
Regulationsmechanismen, die miRNAs auf den NF-κB Signalweg im Zusammenhang mit 
Brustkrebs ausüben. miRNAs sind maßgeblich für die Regualtion der eukaryotischen 
Genexpression auf postranskriptionaler Ebene verantwortlich, durch das Binden ihrer Ziel 
mRNAs über Seed Sequenzen und der daraus folgenden Inhibition der Genexpression. In einem 
genomweiten miRNA Screening konnte in einem vorhergehenden Projekt die miR-30c-2-3p als 
einer der stärksten Negativregulatoren des NF-κB Sigalwegs identifiziert werden. Im Rahmen 
meiner Doktorarbeit habe ich, durch die Kombination von in vitro Daten und öffentlich 
zugänglichen Datensätzen, Mechanismen aufdecken, mit denen die miR-30c-2-3p den NF-κB 
Sigalwegs und den Zellzyklus bei Brustkrebs beeinflusst. 
 
Ich konnte zeigen, dass miR-30c-2-3p sowohl die Expression von TRADD, einem 
Adaptorprotein des TNFR/NF-κB Siganlwegs, als auch die Expression des Zellzyklus Proteins 
CCNE1 direkt beeinflusst. Die ektopische Expression von miR-30c-2-3p regulierte die 
Expression essentieller Cytokine wie IL8, IL6 und CXCL1 herunter, reduzierte die 
Zellproliferationsrate und verminderte die Invasionfähigkeit von MDA-MB-231 
Brustkrebszellen. RNAi-induziertes silencing von TRADD hatte Auswirkungen auf die 
Invasionsfähigkeit und die Cytokin Expression, wie auch schon unter Einfluss von miR-30c-2-
3p. Im Gegensatz dazu hatte die Inhibition von CCNE1 ähnliche Effekte wie miR-30c-2-3p auf 
die Zellproliferation. Die tumorsupressive Rolle der miR-30c-2-3p wurde in einem 781 
Brustkrebsproben umfassenden Datensatz, bestehend aus mRNA und miRNA Expressionsdaten 
bestätigt. Eine erhöhte Expression von miR-30c-2-3p konnte mit einer positiven Prognose 
assoziiert werden. Desweiteren konnte eine gegenläufige Korrelation der Zielgene von miR-
30c-2-3p und miR-30c-2-3p bei diesen Brustkrebspatientinnen beobachtet werden. Diese 
Erkenntnisse sind im Kontext von Brustkrebs wichtig, da der NF-κB Signalweg mit 
Tumorentwicklung, Tumorprogression, Metastasenbildung und Chemotherapie-Resistenz in 
Verbindung gebracht wird. Die miR-30c-2-3p könnte daher ein vielversprechender Kandidat für 
die miRNA basierte Therapie von Brustkrebs sein.  
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1. Introduction 
1.1. Breast cancer  
Breast cancer is a heterogeneous disease which can be defined by molecular subtypes 
that are associated with distinct molecular signatures and clinical outcomes including 
response to drugs. The main molecular subtypes of breast cancer are: luminal A, 
luminal B, human epidermal growth factor receptor 2 (HER2) or ERBB2+ enriched, 
and basal-like tumors [1]. These subtypes are based on gene expression profiling and 
cluster analysis of breast tumors [2-4]. Each of these subtypes is associated with 
different overall survival and unique intrinsic gene expression patterns (Table 1) [3, 5, 
6]. The mutation status of the tumor suppressive gene, TP53 is also significantly 
different in these molecular subtypes with the basal-like tumors having 80%  mutations 
compared to 12% and 29% in luminal A and luminal B, respectively [6]. This data 
showed that the TP53 pathway is largely functional in luminal A tumors but inactivated 
in more aggressive subtypes of breast cancer [6]. 
 
Table 1: Characteristic intrinsic gene expression pattern associated with each 
molecular subtype of breast cancer. Data from [3, 5, 6].  
Molecular subtype  Intrinsic gene expression pattern 
Luminal A High expression of ESR1, GATA3, FOXA1, XBP1 and MYB 
Luminal B Low to moderate expression of ER cluster (above), high 
expression of GGH, LAPTMB4, NSEP1 and CCNE1 
ERBB2+ subtype High expression of ERBB2, all genes within HER2 amplicon 
(including GRB7) and TRAP100, FGFR4, EGFR 
Basal-like  Negative expression for ER cluster and HER2, high expression 
of KRT5, KRT1, ANXA8, CX3CL1, TRIM29, AKT3, MYC 
and gene amplification of 
CCNE1, FGFR1, FGFR2, IGFR1, KIT, MET ,PDGFRA, MYC 
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These molecular subtypes are representative of the biology behind different stages of 
epithelial cell development of the human breast with luminal A and luminal B falling 
under more differentiated tumors compared to the other two subtypes [7]. Luminal A 
and luminal B subtypes are classified as estrogen receptor positive (ER+), with luminal 
A associated with the best prognosis compared to all other subtypes of breast cancer [1]. 
The status of estrogen receptor determined by immunohistochemistry is the most 
relevant independent prognostic and predictive factor for responsiveness to endocrine 
therapy in breast cancer [8]. Estrogen receptor negative (ER-) breast cancer, which 
comprises of ERBB2+ or HER2 enriched and basal subtypes is characterized by the 
absence of estrogen receptor expression [5, 9]. In contrast to estrogen receptor positive 
tumors, estrogen negative tumors do not require estrogen hormone for continual growth, 
and can thus not be treated with standard endocrine therapy, for example tamoxifen or 
aromatase inhibitors [10]. ER negative group of breast cancer also differs from 
ER+/luminal clusters in expression of several additional transcription factors [3]. About 
30% of breast tumors are estrogen receptor negative [5]. Out of these, breast tumors that 
express HER2 can be treated with trastuzumab or lapatinib (effective also against EGFR 
overexpressing breast tumors) [11, 12]. 
 
Basal-like tumors are mostly referred to as triple negative breast cancers (TNBCs) due 
to the lack of expression for ER, PR, and HER2 and constitute 10%-25% of all breast 
tumors [6, 13]. However, only 75% of TNBCs are indeed basal-like tumors [6]. The rest 
includes all other molecular subtypes emphasizing the heterogeneity of triple-negative 
group of tumors [13]. Due to the lack of targeted therapy options in case of basal-like 
tumors, this subtype is associated with poor overall survival and clinical outcome [9, 
10]. Although TNBCs or basal-like tumors are responsive to chemotherapy, still this is 
associated with disease recurrence and progression [13].  
 
Despite major improvements in diagnosis and treatment, breast cancer is still the second 
leading cause of tumor associated death among women worldwide [14]. This 
emphasizes the need to better understand the gene regulation networks deregulated in 
estrogen receptor negative or basal-like tumors to come up with strategies for improved 
therapy and diagnosis. 
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1.2. NF-κB signaling 
NF-κB signaling is a key pathway regulating inflammatory responses, cell proliferation, 
innate immune responses and involved in organogenesis [15]. NF-κB is an evolutionary 
conserved family of transcription factors with 5 members that are structurally related 
and can form homo- or hetero-dimers: RelA (p65), RelB, c-Rel, NF-κB1 (p105 and 
p50), and NF-κB2 (p100 and p52) [15, 16]. RelA (p65), RelB, and c-Rel are produced 
in mature form and have a transactivation domain [17]. NF-κB1 and NF-κB2 are 
translated as large precursors, p105 and p100, respectively. These are processed to 
mature active forms, p50 and p52 respectively [15]. All the 5 members of the family 
share an 300 amino acid domain known as Rel homology region (RHR) responsible for 
nuclear localization, binding to the DNA, dimerization and association with inhibitor 
proteins [17]. In an unstimulated or inactive state, NF-κB proteins reside in cytoplasm 
through non covalent interactions with inhibitory proteins like, IκBβ, IκBα, IκBε, IκBζ, 
Bcl-3, IκBNS and inactive precursor forms of proteins [17, 18]. Upon stimulation with 
appropriate ligand, NF-κB proteins translocate to the nucleus and, as homo or hetero 
dimers, bind to κB DNA sequence motifs thus regulating gene expression [16].  
 
In response to stimuli such as tumor necrosis factor-α (TNF-α), CD40 ligand (CD40L), 
interleukin-1 (IL-1), or lipopolysaccharide (LPS) canonical signaling is activated 
through the IKK (inhibitor of NF-kappa B kinase) complex. This complex consists of 
three protein subunits IKKα, IKKβ (catalytic subunit) and IKKγ (regulatory subunit) 
[15]. An activated complex can then phosphorylate and mark IκB proteins for 
ubiquitination via SCF-type E3 ubiquitin-protein ligase and finally cause degradation by 
the 26S proteasome [19-21]. The classical inhibitor proteins IκBβ, IκBα, IκBε contain 
ankyrin repeat domain and two serine residues within the consensus sequence DSGXXS 
at the N-terminal end of the proteins that are sites for phosphorylation [17]. Upon 
degradation of the inhibitor proteins, nuclear translocation of activated NF-κB to the 
nucleus occurs resulting in gene expression activation [21]. 
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Figure 1: Alternative routes for NF-kB activation. Interaction of TNF receptors (TNFRs) with ligand 
such as TNF-α or LPS causes activation of IKKβ subunit. This subsequently leads to formation of 
heterodimers consisting of RelA and p50 which can translocate to nucleus and activate gene expression 
through canonical pathway. A class of TNFRs known as B-cell receptor for BAFF (BAFF-R) can interact 
with ligands such as BAFF and initiate NF-κB activation through IKKα subunit. This ultimately results in 
formation of heterodimers consisting of RelB and p52 which translocate to nucleus leading to gene 
expression activation through non-canonical pathway for genes involved in B cells function. Figure taken 
and adapted from [20]. 
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There are two types of NF-κB activation pathways, the canonical and the non-canonical 
activation pathway (Figure 1). Canonical pathway mainly activates NF-κB dimers 
consisting of RelA or c-Rel in response to stimuli such as IL-1, TNF-α and LPS [17]. 
These ligands activate TNF receptor–associated factor 2 (TRAF) proteins and 
eventually kinase TAK1, which phosphorylates and activates IKKβ subunit of IKK 
kinase [20]. The signaling activation in response to B-cell-activating factor (BAFF) 
ligand, CD40 ligand or lymphotoxin-β leads to processing of p100 to p52 and is called 
non-canonical NF-κB activation pathway which is mostly active in B-cells [20, 22]. In 
this pathway, IKKα subunit is phosphorylated by NF-κB-inducing kinase (NIK) which 
in turn phosphorylates p100 that form p52 [22]. The activating stimuli such as TNF-α 
and IL-1 also lead to expression of signaling inhibitor proteins such as IκBα, IκBε 
which function to suppress NF-κB activity in a negative feedback loop [17]. Also 
deubiquitinating enzymes like, CYLD (cylindromatosis (turban tumor syndrome)) and 
A20 (tumor necrosis factor, alpha-induced protein 3, TNFAIP3) can act as a negative 
regulators of the signaling [23] to maintain cellular homeostasis. 
 
1.2.1. TNF-α mediated NF-κB signaling 
TNF-α is a key stimulator for canonical, or classical, NF-κB signaling and a member of 
the TNF superfamily [24]. The TNF superfamily comprises 19 ligands including 
lymphotoxins (LT), receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL), 
and TNF-related apoptosis-inducing ligand (TRAIL). These can interact with 29 
receptors from the TNFR superfamily [24]. Most members of the TNF superfamily are 
transmembrane proteins that are released from cell surface through the process of 
proteolysis carried out by proteases [24]. For example, TNF-α is released from the 
surface of cells by the enzyme TACE (TNF-alpha-converting enzyme) [25].  
 
TNF-α is a proinflammatory factor present in the tumor microenvironment that has been 
implicated in diverse roles like cell proliferation, inflammation, regulation of immune 
response and anti-viral response [26, 27]. It can bind to TNF receptors (TNFR1 and 
TNFR2) that are expressed in most cells and tissues [16, 24], and can also bind the 
HER2 receptor tyrosine kinase to activate the MAPK signaling pathway [28]. TNFR1 
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(p55) and TNFR2 (p75) belong to a superfamily of proteins collectively called 
TNF/Nerve Growth Factor (NGF) receptor [29]. The family members of this 
superfamily of proteins are characterized by cytoplasmic domains that lack a distinct 
enzymatic activity and interact with other cytoplasmic proteins to convey biological 
signals [30]. The characteristic response of cells to TNF-α (Figure 2) is mediated 
through involvement of an 80 residue long motif called death domain (DD) [31]. 
Proteins like TNF receptor 1-associated protein (TRADD), Fas-associated death domain 
(FADD) and receptor interacting protein (RIP1) contain this death domain and can 
interact with the cytoplasmic domain of the TNFR1 receptor [32-34].  
 
TRADD overexpression leads to two main cellular responses, activation of NF-κB 
signaling and apoptosis [32]. Interaction of TNF-α with TNFR can also initiate 
apoptosis by engagement of FADD and caspase 8 [16, 35]. However NF-κB signaling 
has a protective role against TNF-α induced apoptosis through expression of survival 
genes such as BCL2L, inhibitors of apoptosis (IAPs), and activation of the AP-1 
transcription factor [16, 36, 37]. This anti apoptotic effect is caused by recruitment of 
TRADD as an adaptor molecule to the cytoplasmic domain of TNFR1. TRADD then 
recruits TRAF2 which in turn interacts with RIP, this cascade ultimately triggering NF-
kB signaling via activation of the IKK complex [16]. 
  
 
13 
 
 
Figure 2: TNF-α mediated activation of cellular signaling. TNF-α activates NF-κB signaling by 
engaging the TRADD–RIP1–TRAF2–TRAF5 complex to TNFR1. This leads to TRAF mediated K63-
linked ubiquitination of RIP1 which induces association with the IKK complex. This in turn leads to 
phosphorylation and K-63 linked ubiquitination of the IKK complex. This ulimately leads to proteasome 
mediated degradation of IκB proteins and translocation of NF-κB dimers to the nucleus and activation of 
gene expression. Figure taken and adapted from [38]. 
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1.2.2. Role of NF- κB signaling in breast tumorigenesis  
NF-κB signaling plays an important role in mammary gland development, especially 
during proliferation of mammary epithelial cells that occurs during pregnancy, 
differentiation at the time of lactation, and apoptosis of the secretory epithelial cells 
during involution [39-41]. These effects are mainly mediated in response to RANKL 
through non-canonical signaling activation [41]. Furthermore, experimental evidence 
from genetically modified mice that have altered NF-κB, IκB, or IKK proteins show 
defects in mammary gland development [15]. Deregulation, i.e. constitutive activation 
of this tightly regulated pathway can lead to tumor initiation and transformation by 
various mechanisms (Figure 3). These include unregulated proliferation of cells, 
evasion of apoptosis, and increased tumor metastasis and angiogenesis [42]. Activated 
NF-κB is mainly responsible for cancer development and is not associated with genetic 
alterations in NF-κB, IKK or other upstream members of signaling [43]. The 
consequence is an excessive production of survival proteins like BCL2L, BCL2 and 
proinflammatory cytokines like IL8, IL6 and CXCL1 which are part of the tumor 
microenvironment. Thus, this signaling also forms a critical link between cancer and 
inflammation [43]. 
 
Activation of NF-κB signaling through the canonical (dimers of p65/p50) and non-
canonical pathways (dimers of p50, p52 and c-Rel) has been shown both in breast tumor 
samples and breast cancer cell lines [44, 45]. Frequently, NF-κB signaling is 
constitutively active, particularly in ER negative breast tumors [46, 47]. This is 
associated with increased cell proliferation, inhibition of apoptosis, metastasis and 
tumor progression thus making NF-κB signaling an attractive target for therapeutic 
intervention. NF-κB signaling has also been implicated in malignant transformation of 
ER positive breast cancer [48]. The hormone independence of ER negative tumors is 
associated with increased NF-κB activity primarily through increased p50 dimers and 
higher Bcl-3 expression which can replace estrogen by providing survival and growth 
signals to the cells [49]. Estrogen receptor mediated signaling on the other hand 
suppresses NF-κB activation and has an anti-inflammatory role, underlining the relation 
between these two signaling pathways in the context of breast cancer [50]. This 
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crosstalk can explain the resistance to antiestrogen therapy including tamoxifen and 
aromatase inhibitors seen in clinics [51].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: NF-κB signaling is implicated in breast cancer by regulating phenotypes like tumor 
initiation, progression, chemoresistance and metastasis. Figure taken and adapted from [40].  
  
NF-κB in    
Breast Cancer 
Metastasis 
uPA ↑ 
MMP-9 ↑ 
TIMP ↓ 
PAI ↓  
Chemoresistance 
TRAF-1 ↑ 
cIAP-2 ↑ 
DAD1 ↑ 
GADD45β ↑ 
GADD153 ↓  
Progression 
Cyclin D1 ↑  
Integrin αV ↑  
IL-6 ↑ 
IL-8 ↑ 
MIP2α ↑ 
INOS ↑ 
COX-2 ↑ 
GRO-1 ↑  
Initiation 
Cyclin D1 ↑ 
c-Myc ↑ 
TP53 ↓ 
GADD153 ↓ 
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1.3. Cell cycle regulation 
The cell cycle in eukaryotes is a highly regulated biological process and has four 
distinct phases: mitosis (M-phase), DNA replication (S-phase), gaps G1 and G2 [52]. 
During the G1 and G2 gap phases, cells synthesize biomolecules such as RNA and 
proteins and perform metabolism, the DNA is replicated in S-phase, while cell division 
occurs during M-phase [53]. The mammalian cell cycle is more complex with five 
distinct cell cycle phases with an additional G0 phase in which cells are in quiescent or 
non-dividing state. Mammalian cells remain in the G0 phase until they receive a growth 
stimulus to activate signaling pathways like MAPK pathway [53]. In the late G1 phase, 
the restriction (R) point defines a critical point in the commitment of cells to the cell 
cycle and after this point cells are no longer sensitive to presence or absence of growth 
factors [54]. There are a number of checkpoints in the course of the cell cycle to 
maintain the integrity of the genome during cell cycle progression [53]. The most 
important member of this system is the TP53 tumor suppressor protein, which either 
causes cell cycle arrest to allow DNA repair to occur in response to DNA damage or 
apoptosis if the damage is too strong [55]. 
 
1.3.1. Cyclins and CDKs in cell cycle control 
Cyclin-dependent kinases (CDKs) are a conserved family of molecules that coordinate 
the events in the cell cycle of eukaryotes [52]. These CDKs work in association with 
proteins named cyclins, because of their oscillating levels in dividing embryonic stem 
cells [56]. There are 9 CDKs (CDK1 - CDK9) and many cyclins (cyclin A - cyclin T) 
known [57]. In mammals four different types of CDKs (CDK1/CDC2, CDK2, CDK4 
and CDK6) combine with four different families of cyclins:  cyclin D (D1, D2 and D3), 
E (E1 and E2), A (A1 and A2) and B (B1, B2 and B3) [58]. Different combinations of 
cyclins and CDKs are involved in cell cycle progression (Table 2). The activity of 
CDKs is kept in check by association with negative regulators known as cyclin-
dependent kinase inhibitors (CDKIs). These CDKIs are produced in response to anti 
mitogenic signals and belong to two main classes of proteins: Cips (CDK interacting 
protein) and INK4 (inhibitor of CDK4) [59]. These proteins are allosteric competitors of 
cyclins for binding to CDKs [58]. 
 
17 
Table 2: Cell cycle phases and their associated cyclin/CDK complexes during cell 
cycle progression. Information taken from [53]. 
Cell cycle phase cyclin/CDK complexes 
Progression through G1 phase cyclin D/CDK4 (CDK6) 
G1/S transition cyclin E/CDK2 
Progression through S phase cyclin A/CDK2 
Progression through G2 phase cyclin A/CDC2 
Progression through M phase cyclin B/CDC2 
 
In the absence of mitogens, the activity of CDKs is off. As a result of this, the CDK 
substrate, retinoblastoma protein (Rb) is hypo-phosphorylated, which leads to inhibition 
of E2F transcriptional activators [60]. However, in the presence of mitogens the 
synthesis of D-type cyclins and their assembly with CDK4/CDK6 lead to 
phosphorylation and release from the Rb tumor suppressor protein, resulting in the 
activation of E2F transcriptional activators [54, 60]. Activated E2F can then induce the 
expression of cyclin E and other proteins that enhance kinase activity of CDK2 thus 
leading to further phosphorylation of Rb [54, 61]. Subsequent degradation of CDK 
activity inhibitor, p21 further drives G1 to S transition [62]. Nuclear p21 can inhibit the 
activity of transcription factors MYC, E2F1, STAT3 involved in cell cycle [62]. 
Cytoplasmic p21 can be phosphorylated by IKKβ (inhibitor of nuclear factor-κB kinase-
β), preventing nuclear translocation and promoting its anti-apoptotic effects [63]. This 
showed direct connection between NF-κB signaling and cell cycle control. 
Phosphorylation of cyclin E by the cyclin E/CDK2 complex leads to proteasome-
dependent degradation of cyclin E once S phase is initiated, this favors association of 
CDK2 with cyclin A [64]. Different combination of CDC2 with cyclin A or cyclin B 
drives the cells through rest of the cell cycle.  
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1.3.2. Role of cyclins in breast tumorigenesis 
Cell cycle regulation is frequently deregulated during tumorigenesis with cancer cells 
exhibiting self-sufficiency of growth signals [65]. CDKs and cyclins are often 
overexpressed in tumor cells as revealed by molecular analysis of human tumors [58]. 
For example, D-cyclins are found to be overexpressed and associated with alterations 
like gene amplification and chromosomal translocations in breast tumors which 
frequently show a high occurrence of cyclin D1 (CCND1) overexpression [58]. 
Transgenic mice overexpressing cyclin D1 in mammary cells undergo abnormal cell 
proliferation including formation of mammary adenocarcinoma [66]. Similar to these 
observations, overexpression of cyclin D2 has been shown to induce cell proliferation 
and to be oncogenic during mammary gland development [67]. This collectively 
showed that long term expression of these two cyclins is involved in breast 
tumorigenesis in mice. Furthermore, the role of cyclin D1 in breast tissue proliferation 
is underlined by the observation that inhibition of cyclin D1 expression selectively 
prevented tumor development occurring from alterations in the Ras and Wnt signaling 
pathways [58]. 
 
E-type cyclins (cyclin E1 and cyclin E2) in combination with CDK2 regulates essential 
processes at G1 to S transition of the cell cycle [68]. The expression of cyclin E is 
higher than the physiological levels in many types of human tumors, and the genomic 
locus (19q12-q13) is frequently amplified [68-70]. Higher levels of cyclin E have been 
implicated in breast tumorigenesis through inactivation of the pRb pathway and 
increased kinase activity causing unrestrained growth [71]. These observations 
underline the importance of both cyclin D and cyclin E in breast tumor formation.  
 
The role of cyclin A1 in formation and progression of tumors has also been studied 
through transgenic mouse models. Overexpression of cyclin A1 proteins in the 
mammary gland of transgenic mouse models leads to an increased cyclin A1 associated 
CDK2 kinase activity [72]. These transgenic mice exhibited abnormalities of nucleus 
like multinucleation and karyomegaly which indicate preneoplastic alterations [72]. 
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1.4. RNA interference 
RNA interference (RNAi) is a mechanism of gene expression regulation in eukaryotes 
which was first discovered in Caenorhabditis elegans in response to double-stranded 
RNA (dsRNA), causing downregulation of complementary target genes [73]. In plants, 
RNAi is a defense mechanism against RNA viruses to stop their replication [74-76]. 
Similar downregulation of gene expression in response to dsRNA is also observed in 
species, such as Drosophila, and many mammals [77-80].  
 
RNAi is operational at the post transcriptional level to repress and regulate gene 
expression. This observation was made in C.elegans where ds RNA resulted in loss of 
expression in corresponding messenger RNAs (mRNA) leaving other regulatory 
elements such as promoters sequences unaltered [73]. At the molecular level, gene 
expression is repressed by small interfering RNA (siRNA) which is either produced 
endogenously or can be artificially introduced into the cell [81]. Endogenous siRNAs 
are typically up to 23 nucleotides long and are cleavage products of dsRNAs which 
correspond to mRNAs and result in post transcriptional silencing of these genes (PTGS) 
[82, 83]. The components of the RNAi pathway were discovered initially in Drosophila 
[84]. A ribonucleoprotein complex called RNA Induced Silencing Complex (RISC) was 
found to be responsible for sequence guided degradation of mRNA [85]. This complex 
consists of Dicer, a ribonuclease III family enzyme, for processing long dsRNAs into 
approximately 22-nucleotide siRNAs, and Argonaute2 protein which is responsible for 
cleavage of target mRNAs and the siRNAs [85]. The RNAi machinery has been 
exploited in a number of studies to specifically repress gene expression in mammals 
[86, 87]. However, introduction of long dsRNA in mammalian cells elicits apoptosis 
and inhibition of protein synthesis due to activation of the PKR (protein kinase R) and 
RNAseL pathway [83, 88]. This effect can be circumvented by introducing only 23 
nucleotide long double stranded siRNAs into mouse or human cells [89]. 
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1.4.1. miRNA  
MicroRNAs (miRNAs) are a class of non protein-coding RNAs that can modulate gene 
expression at the post transcriptional level. As a result, miRNAs regulate key biological 
processes like embryonic development [90]. In contrast to most siRNAs, miRNAs are 
encoded in the genome and transcribed by RNA polymerases ІІ or ІІІ [91]. The first step 
of miRNA biogenesis involves transcription of miRNA genes to form primary or pri-
miRNA [91]. This pri-miRNA is then cleaved by RNase ІІІ endonuclease Drosha to 
form a ~70 nucleotide precursor or pre-miRNA which has a stem loop structure [92]. 
This is then transported into the cytoplasm. There, the second important step during 
miRNA biogenesis is the cleavage by enzyme Dicer RNase ІІІ of pre-miRNA to form 
mature double stranded miRNA of ~22 nucleotide in length [93]. 
 
The first miRNA was discovered in Caenorhabditis elegans, where it was shown that 
lin-4 negatively regulates the translation of lin-14 mRNA by binding to complementary 
sequences within the 3´UTR via antisense RNA-RNA interactions [94]. This 
translational inhibition was found to be important during larval development [94]. This 
was followed by the discovery of miRNA let-7 which, along with lin-4, regulates the 
developmental timing in Caenorhabditis elegans [95]. Since then many more miRNAs 
have been reported in other species as well. In humans, there are currently 2578 mature 
miRNAs and 1872 precursor miRNAs reported to be encoded in the genome [96].  
 
1.4.2. Mechanism of gene regulation 
Processed mature miRNAs are between 21-24 nucleotides long and bind mostly within 
the 3´UTRs of their target mRNAs [93, 97]. This interaction is mediated by the RNA 
induced silencing complex (RISC) and leads to degradation or translational repression 
of the mRNAs depending on the level of complementarity between miRNA or siRNA 
and mRNA (Figure 4A and B) [84, 93]. This interaction is mediated by involvement of 
Argonaute (Ago) proteins [98]. After mediating the cleavage of target mRNA, the 
corresponding miRNA or siRNA can then modulate expression of other mRNAs [93, 
99]. Another proposed model of regulation is through siRNA mediated transcriptional 
silencing of DNA (Figure 4C) [93]. miRNAs bind regions in the 3´UTR of target 
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mRNAs through the so-called seed sequence of 2-8 nucleotides at the 5´ of every 
miRNA [100]. This binding specifies target specificity of the miRNA. More than half of 
the human protein coding genes (approximately 60%) are predicted to be regulated by 
miRNAs [101]. These targets of miRNAs cover a broad range of biological, molecular 
and cellular processes [93]. 
 
1.4.3. miRNAs and their role in breast cancer 
miRNA mediated regulation plays an important role in development and progression of 
cancer [98]. They can act both as tumor suppressors or oncogenes, depending upon the 
spectrum of targets regulated by the respective miRNAs [98]. For example miR-21 acts 
as an oncogene and promotes breast cancer via regulation of anti-apoptotic factor BCL-
2 [102]. Frequently, altered expression of miRNA genes has been found in a number of 
tumor types and between normal and neoplastic tissues. Their role in carcinogenesis and 
specifically in breast cancer is increasingly studied [103-105]. Moreover, miRNAs have 
distinct expression patterns across different subtypes of breast cancer and play an 
important role in defining the associated gene expression pattern [106]. Recently, Ward 
et al. showed that miR-519a acts as a master regulator of cell cycle in ER positive breast 
cancer patients by targeting key proteins of cell cycle like RB1, PTEN and p21 [107]. 
Figure 4: Mechanisms of miRNA/siRNA mediated gene regulation.(A) Cleavage of complementary 
mRNA caused by both miRNA or siRNA. (B) Repression of mRNA translation caused by both miRNA 
or siRNA. (C) Transcriptional silencing mediated by siRNA. Figure taken and adapted from[93]. 
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miRNAs have also been implicated to induce or revert drug resistance against standard 
chemotherapy and targeted therapies [98]. Trastuzumab is a part of targeted drug 
against overexpressed HER2. miR-21 has been known to be upregulated in trastuzumab 
resistance in both in vitro and in vivo conditions which is associated with poor response 
of patients [108]. Taking into consideration their central role as negative regulators of 
biological processes, miRNAs can be used as biomarkers or targets in cancer therapy. 
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1.5. Aim of the study 
The aim of my PhD study was to find and characterize novel miRNA regulators of NF-
κB signaling that can be potentially used as biomarker or in miRNA based therapy in 
breast cancer patients. This included elucidation of the mode of gene regulation and 
cellular phenotypes affected by the miRNA. This consisted of two main parts:  
1) Identifying and validating target genes responsible for the phenotype caused by 
the miRNA. 
2) Establishing clinical relevance of in vitro findings by analyzing breast cancer 
patient datasets. 
 
In addition to the primary focus of my research project that is outlined in this thesis, I 
contributed to several other projects that were related to breast cancer, some of which 
have already been published while others are still underway (see chapter 5 “Own 
publications” for details). I have not included any of this work in the thesis because 
these studies were not along the main focus of my PhD research project.  
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2. Materials and Methods 
 2.1. Materials 
2.1.1. Instruments 
Table 3: Instruments used during this study. 
Instrument Company   
ABI Prism 7900HT Applied Biosystems  
Axiovert 25 light microscope Carl Zeiss 
Bacterial incubator (37oC) Memment 
Balance Kern, EW 
Cell counter CASY Casy, Innovatis 
Cell culture hood HERA Safe  Thermo Scientific  
Cell culture incubator (37oC) Heraeus, BBD6220 
Centrifuges Eppendorf, Heraeus  
DNA gel apparatus Renner GmbH 
Electrophoresis Power Supply Pharmacia 
Flow Cytometer FACS Calibur Becton-Dickenson 
Gel documentation system Herolab 
Infinite M200 microplate reader TECAN 
Light Microscope Hund, Wetzlar 
Microwave Panasonic 
Nanodrop ND-1000 spectrophotometer Nanodrop 
Odyssey Infrared Imaging System Li-Cor Biosciences 
Olympus Scan^R microscope Olympus 
pH meter HANNA, Kehl 
Pipetteboy Integra Biosciences 
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Pipetteman Gilson 
Protein Gel Apparatus Invitrogen 
Sentrix Human HT-12 v4 BeadArrays Illumina 
Shaking bacterial incubator (37oC) HT INFOS Minitron 
Thermocycler Applied Biosystems 
Trans-Blot SD Semi-Dry Electrophoretic 
  
Bio-Rad 
Trans-Blot® Electrophoretic Transfer Cell Bio-Rad 
Vortex mixer NeoLab 
Waterbath Grant SUB14 
xCelligence Real-time cell analyzer (RTCA) Roche 
 
2.1.2. Molecular biology kits 
Table 4: Molecular biology kits used and during this study. 
Reagents and kits Company 
ABSOLUTE qPCR ROX mix  Thermo Scientific  
A protein assay reagent Pierce  
beta-glo® Luminescent Assay Kit Promega  
Caspase-Glo 3/7 Assay Promega  
cDNA synthesis kit Thermo Scientific  
Cell titer blue Promega  
Dual luciferase assay Promega  
miRCURY LNA™ Universal RT microRNA 
PCR 
Exiqon  
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miRNeasy Mini kit Qiagen  
MiniElute® PCR purification kit Qiagen  
QIAprep Spin Midiprep Kit  Qiagen  
QIAprep Spin Miniprep Kit  Qiagen  
QIAquick Gel Extraction Kit Qiagen  
QuikChange Lightning Site-Directed 
Mutagenesis kit 
Stratagene  
RevertAid™H Minus First Strand cDNA 
synthesis kit 
Fermentas  
RNeasy Mini Kit Qiagen  
TA-Cloning Kit Invitrogen  
Wizard® SV Gel and PCR Clean-Up System Promega  
 
2.1.3. Chemicals, reagents and enzymes 
Table 5: Chemicals used during this study. 
Chemical  Company 
7 Aminoactinomycin D (7-AAD) BD Pharmingen  
Acrylamide/bisacrylamide 37.5:1 Roth  
Agarose  Roth  
Agar Sigma-Aldrich  
Ammoniumperoxodisulfate (APS) Roth  
Ampicillin Sigma-Aldrich  
Anti- phosphatase PhosSTOP Roche  
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Bacto-Trypton Difco  
Blue Prestained Protein Molecular Weight 
Marker Mix 
Pierce  
Biozym Sieve GP Agarose Biozym 
BSA PAA Laboratorien 
Coelenterazine Sigma 
CoenzymeA AppliChem 
Chloroform Merck  
Cytofix/Cytoperm Buffer BD Pharmingen  
Dimethylsulfoxide (DMSO) Sigma 
D-luciferin AppliChem 
6x DNA loading dye Fermentas  
DNA Molecular Weight Marker PeqGold 
Leitermix 
PeqLab 
DNase, RNase free  Qiagen 
deoxynucleoside triphosphate (dNTPS) New England Biolabs  
EDTA Merck  
Ethanol Merck  
Glycerol Roth 
Glycine Gerbu 
Hoeschst-33258 Sigma 
HCl Sigma 
Isopropanol Sigma  
Lipofectamine2000 TM Invitrogen 
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Methanol Sigma-Aldrich  
MgSO4 Sigma-Aldrich  
M-PER lysis buffer Thermo Scientific  
Na2HPO4 Sigma 
NaCl AnalaR NORMAPUR 
NaH2PO4 Sigma 
NaOH Fluka 
non-DEPC treated nuclease-free water Ambion 
Paraformaldehyde Sigma-Aldrich  
Perm/Wash buffer BD Pharmingen  
Phusion® Hot Start DNA Polymeras New England Biolabs  
protease inhibitor Complete Mini Roche 
4× Roti Load Roth 
Restriction enzymes NEB 
SDS Roth 
Skimmed milk powder Roth  
SOC medium Invitrogen 
sodium citrate tribasic dehydrate AppliChem 
sodium deoxycholate Sigma 
SYBR Green master mix, Universal RT, 25ml Exiqon 
TEMED Roth  
T4 DNA ligase NEB 
Tricine Roth 
Tris HCl Sigma 
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Tris-base Sigma  
Triton X-100 Sigma 
Tween 20 Sigma 
WST-1 proliferation assay Roche 
 
2.1.4. Consumables 
Table 6: Consumables used during this study. 
Name Company 
1.5 mL microcentrifuge tube Eppendorf 
10cm Petri dish TPP 
15mL conical tube BD Falcon 
2 mL microcentrifuge tube Eppendorf 
50mL conical tube BD Falcon 
6-well plate, flat bottom, transparent Nunc  
96-well plate, flat bottom, transparent BD Falcon 
96-well plate, flat bottom, white Perkin Elmer 
384-well plate Applied Biosystems  
Blotting paper Whatman  
Cell Culture Flasks, T-25, T-75 TPP  
Cell Scraper Corning 
Cryovials 1.8mL Nunc 
Facs tubes BD Bioscience  
Falcon tubes Corning  
Filter tips, 10μL, 20μL, 100μL, 200μL, 1000μL Neptune 
PCR strips Steinbrenner 
PVDF membrane (0.45µm) Amersham  
RTCA CIM-plates Roche 
RTCA E-plates Roche 
Serological pipettes 2.5mL, 5mL, 10mL, 25mL BD Falcon 
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Adhesive Optically Clear Plate Seal Thermo Scientific 
PVDF membrane Immobilon-P Millipore 
Sentrix Human HT-12 v4 BeadArrays Illumina 
Whatman 3 MM filter paper GE Healthcare 
 
2.1.5. Bacterial strains and media  
E. coli DH5alpha strain from Invitrogen and XL10-Gold ultracompetent cells from 
Stratagene were used in molecular cloning experiments. 
 
Table 7: Bacterial media composition. 
Bacteria culture media 
Luria-Bertani (LB)                              
 
10 g Bacto-trypto, 5 g yeast extract, 10g NaCl  
Dissolved in water up to 1L and autoclaved. 
LB agar 15g of LB agar in 1L of the LB medium and autoclaved. 
 
 
2.1.6. Cell lines 
Table 8: Cell lines used in this study and their sources. 
Human cell 
line 
Cancer type Cell type/disease Purchased from 
HEK293FT Embryonic kidney Epithelial Invitrogen 
MCF10A Non-tumorigenic 
breast 
Mammary epithelial ATCC  
SKBR3 Breast cancer Adenocarcinoma ATCC  
MDA-MB-231 Breast cancer Adenocarcinoma ATCC  
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T47D Breast cancer Ductal 
adenocarcinoma 
ATCC  
UACC812 Breast cancer Ductal carcinoma ATCC  
BT474 Breast cancer Ductal carcinoma ATCC  
ZR7530 Breast cancer Ductal carcinoma ATCC  
 
2.1.7. Cell culture media  
Table 9: Cell culture media components and their manufacturing companies. 
Name Company 
0.25% trypsin EDTA solution GIBCO, Invitrogen 
bovine insulin  Sigma 
Choleratoxin Sigma 
DMEM GIBCO, Invitrogen 
DMEM F12 GIBCO, Invitrogen 
DMSO  PAN Biotech 
DPBS GIBCO, Invitrogen 
Fetal Bovine Serum GIBCO, Invitrogen 
Geniticin Sigma 
Horse serum GIBCO, Invitrogen 
Hydrocortisone Sigma 
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Leibovitz’s L-15 GIBCO, Invitrogen 
L-glutamine, 200mM GIBCO, Invitrogen 
McCoy´s 5A medium GIBCO, Invitrogen 
MEM GIBCO, Invitrogen 
Non-essential amino acids (100x) GIBCO, Invitrogen 
OptiMEM GIBCO, Invitrogen 
Phosphate buffered Saline (PBS) GIBCO, Invitrogen 
Penicillin/Streptamycin GIBCO, Invitrogen 
Recombinant human EGF BD Biosciences 
Recombinant human LPS Sigma 
Recombinant human TNF-α Sigma 
RPMI 1640 (A10491-01) GIBCO, Invitrogen 
Sodium pyruvate, 100mM GIBCO, Invitrogen 
Streptomycin sulfate GIBCO, Invitrogen 
 
2.1.8. Plasmids 
Table 10: Plasmids used during this study. 
Name Source 
3xKBL Kindly provided by Prof. George Mosialos 
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pMIR-REPORT β-gal vector Ambion 
psiCHECK2 Promega 
 
2.1.9. Software and databases 
Software 
Adobe Photoshop CS3, Adobe   
CellQuest Pro, BD Biosciences  
GraphPad Prism, GraphPad Software, Inc  
Lasergene, DNAstar 
Odyssey software, Li-cor biosciences, Lincoln 
SDS 2.2, Applied Biosystems 
xCelligence Real Time Cell Analyzer (RTCA) software 1.2 
 
Databases 
GEO, http://www.ncbi.nlm.nih.gov/geo/ 
KEGG pathway database, http://www.genome.jp/kegg/pathway.html 
miRWalk, http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ 
MetaCore™, http://thomsonreuters.com/metacore/  
NCBI, http://www.ncbi.nlm.nih.gov/ 
PrimerX, http://www.bioinformatics.org/primerx/ 
DAVID, http://david.abcc.ncifcrf.gov/ 
 
2.1.10. Primers 
All primers used for sequencing, cloning or qRT-PCR were purchased from Sigma-
Aldrich. 
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Sequencing primers 
psiCHECK_seq_fwd: 5´ CCAGGATTCTTTTCCAATGC 3´ 
psiCHECK_seq_rev: 5´ CGAGGTCCGAAGACTCATTT 3´ 
 
Table 11: Sequences of PCR primers used for cloning and mutagenesis of TRADD 
and CCNE1 3´ UTR. 
Name Sequence(5´->3´) 
TRADD_UTR-for CTCGAGTCTGCGGCTATTGCTGAAC 
TRADD_UTR-rev GCGGCCGCTTCTCACATCAAAATCCGTG 
TRADD_MUT-for GAGATCAGCCTCACCAAGACCCATCCCAGAAGCGG 
TRADD_MUT-rev CCGCTTCTGGGATGGGTCTTGGTGAGGCTGATCTC 
CCNE1_UTR-for CTCGAGCCACGTTCTCTTCTGTCTGTTG 
CCNE1_UTR-rev GCGGCCGCAATGGATAGATATAGCAGCACTTAC 
CCNE1_MUT-for GCTACTTGACCTAAGGGACCGGGACAACAACAAAAGCTTGAAG 
CCNE1_MUT-rev CTTCAAGCTTTTGTTGTTGTCCCGGTCCCTTAGGTCAAGTAGC 
 
Table 12: Sequences and Universal Probe Library (UPL) probe numbers of genes 
analyzed by Taqman qRT-PCR. 
Name Sequence (5'->3') UPL Probe 
GAPDH_L AGCCACATCGCTCAGACAC  #60 
GAPDH_R GCCCAATACGACCAAATCC  #60 
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IL8_L AGACAGCAGAGCACACAAGC #72 
IL8_R ATGGTTCCTTCCGGTGGT #72 
CXCL1_L TCCTGCATCCCCCATAGTTA #52 
CXCL1_R CTTCAGGAACAGCCACCAGT #52 
IL6-L GCCCAGCTATGAACTCCTTCT  #45 
IL6-R GAAGGCAGCAGGCAACAC  #45 
HPRT-1_L TGACCTTGATTTATTTTGCATACC #73 
HPRT-1_R CGAGCAAGACGTTCAGTCCT #73 
TRADD_L CAGAAGGTGGCAGTGTACAGG #53 
TRADD_R CAGCATCTGCAGCACGTC #53 
CCNE1_L GGCCAAAATCGACAGGAC #36 
CCNE1_R GGGTCTGCACAGACTGCAT #36 
MMP-9_L GAACCAATCTCACCGACAGG #53 
MMP-9_R GCCACCCGAGTGTAACCATA #53 
MYC_L CACCAGCAGCGACTCTGA #43 
MYC_R GATCCAGACTCTGACCTTTTGC #43 
CSF2_L TCTCAGAAATGTTTGACCTCCA #1 
CSF2_R GCCCTTGAGCTTGGTGAG #1 
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CCND1_L GAAGATCGTCGCCACCTG #67 
CCND1_R GACCTCCTCCTCGCACTTCT #67 
 
Primers for miRNA detection 
miRNA specific primer sets for miR-30c-2-3p, SNO38b and SNO48 were purchased 
from Exiqon. SNO38b and SNO48 were used for normalization of miRNA expression 
analysis.  
 
2.1.11. siRNAs and miRNAs 
Table 13: siRNA and miRNAs used during this study 
 
Table 14: Sequences of siRNAs used for targeting and knocking down the 
expression of RELA, TRADD, CCNE1.  
Gene siRNA 
ID 
Sequence 
  Sense Antisense 
RELA s11914 CCCUUUACGUCAUCCCUGAtt UCAGGGAUGACGUAAAGGGAt 
TRADD s16607 GCGCAUACCUGUUUGUGGAtt UCCACAAACAGGUAUGCGCtg 
CCNE1 118605 CCGGGUUUACCCAAACUCAtt UGAGUUUGGGUAAACCCGGtc 
Name Company 
miRCURY LNA microRNA inhibitors Exiqon  
miRNA mimics Dharmacon  
siRNA oligos Ambion  
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2.1.12. Antibodies 
Table 15: Primary antibodies used in this study. 
Detected protein Catalog no. Host Company 
Actin (20-33) A5060 Rabbit Sigma 
NF-κB p105/p50 3035 Rabbit  Cell signaling 
Phospho NF-κB p105/p50 
(Ser933) 
18E6 Rabbit Cell signaling 
Phospho-IKKα 
(Ser176)/IKKβ (Ser177)  
C84E11 Rabbit Cell signaling 
IKKβ 2C8 Rabbit Cell signaling 
IKKα 3G12 Mouse Cell signaling 
GAPDH 14C10 Rabbit Cell signaling 
TRADD sc-7868 Rabbit Santa Cruz Biotechnologies 
CCNE1 sc-247 Mouse Santa Cruz Biotechnologies 
 
Table 16: Secondary antibodies used in this study. 
Detected protein Catalog no. Company 
IRDye®680_rabbit 926-68071 Li-COR 
IRDye®680_mouse 926-68070 Li-COR 
IRDye®800_rabbit 926-32211 Li-COR 
IRDye®800_mouse 926-32210 Li-COR 
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2.2. Methods 
2.2.1. Cell Culture  
Cell lines were cultured in media compositions (Table 17) according to ATCC 
recommendation.  
Table 17: Media composition used for cell culture of different cell lines  
Cell line Base medium Supplements 
HEK293FT DMEM 10%FCS, 1%L-Glu, 1% non-essential aminoacids, 
1% Penicillin/Streptomycin, 1% Geneticin 
MCF10A 
(growth) 
DMEM-F12 5% Horse serum, 20ng/ml EGF, 0.5µg/ml 
Hydrocortisone, 100ng/ml Cholera toxin, 
0.01mg/ml bovine insulin  
MCF10A 
(resuspension) 
DMEM-F12 20% Horse serum 
SKBR-3 Mc Coy´s 5A 10%FBS, 1% Penicillin/Streptomycin 
MDA-MB-231 Leibovitz´s L-
15  
10% FCS, 1% non-essential amino acids, 15g/L 
NaHCO3, 1% Penicillin/Streptomycin 
T47D RPMI-1640  10%FBS, 0.2 Units/ml bovine 
Insulin, 1% Penicillin/Streptomycin 
ZR-75-30 RPMI-1640 10%FBS, 1% Penicillin/Streptomycin 
UACC812 Leibovitz´s L-
15  
20% FBS, 1% Penicillin/Streptomycin, 20ng/ml 
of EGF, 2 mM L-glutamine 
BT 474 DMEM 10%FBS, 1% Penicillin/Streptomycin;  
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Cell lines were checked for mycoplasma contamination and verified at the cell line 
authentication service at the DKFZ Core Facility. Human recombinant TNF-α was 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and used at a final concentration 
of 20 ng/ml. Lipopolysaccharides from Escherichia coli 0127:B8 (Sigma-Aldrich) and 
used at a final concentration of 10 ng/ml.  
 
2.2.2. Transfections 
All transfections were performed in antibiotic free media using Lipofectamine 2000 (LF 
2000) transfection reagent from Invitrogen (CA, USA). LF 2000 is a formulation of 
cationic lipid which forms complexes with DNA/RNA which can deliver these nucleic 
acids to adherent cells. Cells were seeded in full growth media and transfected when 
they reached 70-90% confluency. Short interfering (si) RNAs for TRADD, RELA and 
CCNE1 were used to knockdown respective proteins and mRNA. Si negative control 
(NTC) was used as a non-targeting control. miRNA-30c-2-3p mimic and mimic control 
(mimic CTRL) was used to overexpress miRNAs. siRNAs and miRNAs were used at a 
final concentration of 30 nM each using Lipofectamine 2000 transfection reagent.  
 
2.2.3. NF-κB reporter luciferase assay 
NF-κB reporter assay was used to study the effect of miRNA overexpression or gene 
knockdown on activation of signaling pathway. For performing NF-κB reporter assay, 
HEK293FT cells were seeded at a density of 6000 cells per well in 96-well plates. 24 
hours later cells were transfected with miRNA mimic or siRNAs, together with the NF-
κB reporter 3xΚBL plasmid which contains 3 consensus NF-κB binding sites upstream 
of the firefly gene (provided by Prof. Mosialos) and pMIR-REPORT β-gal vector. Cells 
were stimulated with TNF-α (20 ng/ml) or LPS (10 ng/ml) 48 hours after transfection, 
and luciferase activity was measured after 5 hours. β-galactosidase which is driven by 
CMV promoter activity was used for normalization, and measured by beta-glo® 
Luminescent Assay Kit (Promega, Madison, WI, USA). For measuring luminescence, 
medium was aspirated from wells and cells were washed with PBS. Later cells were 
lysed in 100 µl per well of M-PER or lysis buffer for mammalian cells for 10 min at 
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room temperature. Cells were carefully resuspended in order to insure complete lysis. 
Luminescence intensity of each well was measured by the plate reader (TECAN 
infinite200 microplate reader). For data analysis, the ratio of firefly over β-galactosidase 
readouts was evaluated for each well.  
 
2.2.4. 3´UTR targeting luciferase assay  
To prove direct targeting by miR-30c-2-3p, 3´UTRs of TRADD (NM_003789) and 
CCNE1 (NM_001238) were cloned downstream of Renilla luciferase into psiCHECK2 
vector using XhoI and NotI restriction sites. 3´UTR was PCR amplified from human 
genomic DNA of the HEK293 cell line. For introducing mutation in miRNA binding 
site, QuikChange Lightning Site-Directed Mutagenesis kit was used. The master mix 
was made as given in Table 18. Primers were designed using PrimerX tool 
(http://www.bioinformatics.org/primerx/). The PCR program used was: 95°C for 2 
minutes, 18 cycles of 95°C for 20 seconds, 60°C for 10 seconds and 68°C for 3 minutes. 
This was followed by a final extension for 68°C 5 minutes. The PCR product was then 
digested with 2 µl of DpnI restriction enzyme for 5 minutes at 37°C. XL10-Gold 
ultracompetent cells were transformed with the PCR product using the heat shock 
method. Bacterial cells were later plated onto ampicillin resistant agar plates and 
incubated at 37°C overnight. Next day colonies were picked and inoculated in LB 
medium with ampicillin. 24 hours later DNA was purified using midi prep kit and sent 
for sequencing. 
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Table 18: Master mix composition per reaction. 
 
For performing the assay, cells were co-transfected with mimic miRNAs and psicheck 
vectors (wild type or mutated) in MDA-MB-231 cells. 48 hours after transfection 
Renilla and firefly luciferase activities were determined using plate reader (TECAN 
infinite200 microplate reader). No stimulation was used for these experiments. For data 
analysis, the ratio of Renilla over firefly (used for normalization) readouts was 
computed for each well. 
 
2.2.5. Whole transcriptome profiling 
MDA-MB-231 cells were transfected with miR-30c-2-3p or mimic control in 6-well 
plates. Cells were harvested 48 hours later and total RNA was isolated using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
miRNA overexpression was confirmed using qRT-PCR. Quality control of total RNA 
(Agilent bioanalyzer, Santa Clara, CA, USA) and gene expression profiling (Illumina 
whole genome Bead Chip® Sentrix arrays HumanHT-12 v4, San Diego, CA, USA) 
were performed by the DKFZ microarray core facility. Expression profiling data was 
Master mix for mutagenesis Volume 
10x reaction buffer  5 µl 
DNA template (50 ng)  1 µl 
Primer_mut-forward (10 µM) 2 µl 
Primer_mut-reverse (10 µM) 2 µl 
dNTP mix (10 mM)  1 µl 
QuikSolution reagent 1,5 µl  
Water 37,5 µl  
QuikChange Lightning Enzyme 1 µl 
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normalized and analyzed for changes in expression levels using the vsn bioconductor 
package in R (http://www.bioconductor.org/packages/2.12/bioc/html/vsn.html). 
 
2.2.6. Quantitative Real-Time PCR 
For protein coding genes, primers and probes for TaqMan® qRT-PCR were designed 
using the Universal Probe Library (UPL) site (https://lifescience.roche.com/shop/home). 
UPL technology from Roche (Roche, Penzberg, Germany) is based on short hydrolysis 
probes whose 5´ end is labelled with fluorescein (FAM) and 3´ end has a quencher dye. 
These probes (165 in total) are 8-9 nucleotides long and have Locked Nucleic Acids 
(LNAs) incorporated into them. Primer sequences used for genes of interests and 
corresponding probes from the Universal Probe Library are listed in materials section. 
For mRNA qRT-PCR, RevertAid™H Minus First Strand cDNA synthesis kit from 
Fermentas (Karlsruhe, Germany) was used for the synthesis of cDNA according to the 
manufacturer’s instructions. For the quantification of mRNA of interest, 10 ng of cDNA 
made from equivalent RNA was used per well of 348 plate. 5μl of cDNA (2ng/μl) was 
added with 6μl of enzymatic master mix (Table 19), with 11μl of total volume in each 
well.  
 
Table 19: Master mix composition per reaction. 
Master mix composition                           Volume 
ABsolute QPCR Mix 5.5μl 
Forward primer (10 μM) 0.11μl 
Reverse primer (10 μM) 0.11μl 
UPL probe 0.11μl 
Nuclease free water 0.17μl 
 
This master mix was then pipetted on 384 well plate along with cDNAs in triplicates. 
The PCR program used for the qRT-PCR was 2 minutes at 50°C followed by 15 
minutes at 95°C to activate the master mix. This was followed by 45 cycles of 15 
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seconds at 95°C and 60 seconds at 60°C. After finishing the PCR run, raw Ct value data 
was retrieved using the SDS software v2.1. GAPDH and HPRT were used as 
normalizing controls for mRNA expression analysis. Results were analyzed using 2(-
Delta Delta C(T)) method [109].  
 
For miRNA quantification using TaqMan®, first miRNA was isolated using the 
miRNeasy Mini kit (from Qiagen) according to the manufacturer’s recommendations. 
Exiqon miRNA Universal Reverse Transcription kit was used for miR-30c-2-3p 
detection. In the first step for reverse transcription, the template RNA samples were 
adjusted to a final concentration of 5 ng/μl using nuclease free water. Then, a master 
mix (Table 20) was prepared. 
 
Table 20: Master mix composition per reaction. 
Master mix composition per reaction        Volume 
5x Reaction Buffer 4 μl 
Nuclease-free water 10 μl 
Enzyme mix 2 μl 
template RNA (5 ng/μl) 4 μl 
 
The reaction mixture was incubated for 60 minutes at 42°C. Later, the reverse 
transcriptase was heat inactivated at 95°C for 5 minutes and immediately transferred to 
4°C. All reactions were diluted with nuclease-free water to a 1:20 ratio. miR-30c-2-3p, 
SNO38b and SNO48 specific primer sets were purchased from Exiqon (Vedbaek, 
Denmark). For the quantitative miRNA expression studies using the Exiqon miRNA 
qRT-PCR assay, 4 μl of the 1:20 diluted RT reaction were mixed with 5 μl SYBR green 
master mix and 1 μl of primer mix, yielding 10 μl total sample volume (per reaction). A 
384-well plate layout document was prepared using the SDS software. The PCR 
program of the RT-PCR followed by a melting curve analysis was 10 minutes at 95°C 
to activate the master mix. This was followed by 45 cycles of 10 seconds at 95°C and 
60 seconds at 60°C. After finishing the PCR, raw data was evaluated using the SDS 
 
44 
software v2.1. SNO38b and SNO48 were used for normalization in miRNA expression 
analysis. 
 
2.2.7. Immunoblotting 
For cell lysate collection, cells were transfected previously in 6-well plates. 48 hours 
after transfection with miRNA or siRNA, medium was aspirated from the cells and they 
were washed with ice-cold PBS. Cells were then lysed in M-PER supplemented with 
protease inhibitor (Complete Mini EDTA-free proteinase inhibitor, Roche) and 
phosphatase inhibitor (Phospho-Stop, Roche). 70µl of this mixture was added on cells, 
and cells were detached by scraping. Cell lysate was then incubated in 4°C for 20 
minutes on a vertical rotor. Later the lysate was centrifuged at 13,000 rpm for 15 
minutes at 4°C and clear supernatant was transferred to a new 1.5 ml tube which was 
stored at -80°C. Protein concentration of samples was quantified using Thermo 
Scientific™ Pierce™ BCA™ Protein Assay according to the manufacturer’s 
instructions. 
 
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) was used to 
separate proteins according to their molecular weights. 15 μg of total protein lysate was 
mixed with protein loading buffer (4x Roti Load) and denatured for 5 minutes at 95 °C. 
Denatured proteins were loaded unto mini polyacrylamide gel (3% stacking gel/12% 
separating gel) along with the molecular weight protein marker (Precision Plus 
ProteinTM Dual Color Standard). The gel was run at 120 Volt for 70 minutes allowing 
separation of proteins, tracked with the help of ProteinTM Dual Color Standard marker. 
  
Separated proteins were then transferred onto Immobilon-P membrane (Millipore) using 
semi dry transfer. The membrane was activated in absolute ethanol for 1 min and later 
transferred to anode solution II for 10 minutes. Whatman filter papers were soaked and 
equilibrated in blotting solutions. Four filter papers were soaked in anode solution I, two 
in anode solution II and six in cathode solution. The gel was placed on top of the 
activated membrane, and placed in between soaked whatman filter papers. Semi-dry 
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transfer was performed in the Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell 
for 1 hour at 25 Volt. 
 
The membrane was blocked after completion of transfer for 1 hour at room temperature 
with 5% non-fat milk made in in 1x TBST buffer. Later the membrane was incubated 
overnight with respective primary antibody at 4°C, using a 1:1000 dilution in 1xTBST. 
Next day, the membrane was washed 3x 5 minutes with 1xTBST, incubated for 1 hour 
at RT with the secondary antibody (IRDye®680 or IRDye®800), using a 1:10000 
dilution in 1xTBST and later washed 3x5 minutes with 1x TBST. The bands were 
visualized using an Odyssey scanner (LI-COR). 
 
2.2.8. Cell proliferation and apoptosis assays 
Cells were transfected in 96-well white plates in 100µl of full growth media. 72 hours 
after transfection with miRNAs/siRNAs, cell viability and proliferation was measured 
using either WST reagent from Roche (Penzberg, Germany) or Celltiter Blue from 
Promega (Madison, WI, USA). WST measures the levels of NAD(P)H in viable and 
metabolically active cells. 10 µl of WST was added to each well. After 3 hours of 
incubation, absorbance was measured at 460 nm. Celltiter Blue on the other hand 
measures the ability of viable cells to reduce resazurin to resoruﬁn, a fluorescence 
product that can be read at 560Ex/590Em. 20 µl of Celltiter Blue was added to each 
well and incubated for 3 hours before the measurement. Apoptosis was measured using 
caspase glo 3/7 assay kit from Promega (Madison, WI, USA). It is a luminescence 
based assay that measures the activities of caspase 3 and caspase 7. The luminescence 
measured is proportional to the amount of active caspase3/7. 100µl of reagent was 
added to each well and luminescence was measured in a plate reader after one hour 
incubation at room temperature. All experiments were performed according to the 
manufacturer's recommendations. 
 
7-AAD (7-Aminoactinomycin D) and BrdU (5-bromo-2'-deoxyuridine) staining for cell 
cycle assays were carried out according to the manufacturer's protocol (BD Pharmingen 
San Diego, CA, USA). 7-AAD is a DNA intercalating dye and florescent in nature. It is 
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excluded from live cells and therefore cells need to be fixed and permeabilized, to allow 
binding with 7-AAD. BrdU is a chemical analogue of thymidine and can get 
incorporated specifically in cells in S-phase of cell cycle. Monoclonal antibodies 
directed against BrdU can then be used to detect and differentiate dividing from not 
dividing population of cells. For performing the assay, cells were seeded in 24-wells 
plate in full growth media. 72 hours after transfection with miRNA/siRNAs the cells 
were incubated with BrdU at a final concentration of 1 µM for 1 hour at 37ºC 
temperature. Cells were then harvested and treated with DNase1 for one hour at 37ºC. 
Later, cells were washed and resuspended in anti-BrdU FITC-conjugated antibody 
purchased from BD Pharmingen (San Diego, CA, USA). Half an hour later cells were 
washed and resuspended in 7-AAD solution for another half an hours. Stained cells 
were then measured by flow cytometry using a FACS Calibur (BD Biosciences, 
Heidelberg, Germany) and Cell Quest Pro software (BD Biosciences, Heidelberg, 
Germany) was used for data analysis. No stimulation was used for cell viability, 
apoptosis and cell cycle progression experiments. 
 
For direct cell counting of cells, Olympus ScanR high-content screening microscope 
was used. Cells were seeded in glass bottom square well MatriPlates and transfected 
with miRNA or mimic control. Hoeschst-33258 diluted to 1:5000 in starvation medium 
was used to stain DNA of cells. After 30 minutes, cells were washed with PBS and 
replaced by starvation media. The florescence intensity was used to count the DNA 
content of cells. Analysis of the images was performed using ScanR analysis software. 
 
2.2.9. Invasion assay 
Invasion experiments were performed using a Real Time Cell Analyzer (RTCA, 
xCELLigence, Roche, Germany). This instrument detects changes in electric cell 
impedance upon cell attachment or cell doubling. Cell index (CI) is measured as a 
function of electrical impedance and gives a measure of cell number. CIM plates were 
used to record the impedance of the invading cells. MDA-MB-231 cells were 
transfected in 6-well plates. 24 hours after transfection, cells were starved overnight in 
0.5% FBS medium. The next day, cells were trypsinized, washed once with starvation 
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medium, counted using a CASY cell counter and adjusted to a cell number of 75,000 
cells/100 µL in starvation medium. The upper chamber was coated with growth factor 
reduced matrigel matrix from Corning (Tewksbury, MA, USA) at a dilution of 1:30 in 
starvation media. Matrigel was allowed to solidify in the upper chamber of CIM plate 
for 4 hours at 37°C. The cell suspension was then seeded on top of the matrigel. The 
lower compartment was filled with 175 µl full growth medium. CIM plates were placed 
in RTCA instrument and cell index values were recorded with a time-interval of 15 
minutes for a total of 15 hours. 
 
2.2.10. Wound healing assay 
MCF-10A cells were seeded in glass bottom plate at a density of 55,000 cells per well 
in full growth medium. Next day, cells were transfected with siRNAs or miRNAs in 
antibiotic free medium. 24 hours after transfection the full growth medium was removed 
and replaced with starvation medium. After over 16 hours of starvation, cells were 
stained with CMFDA (5-Chloromethylfluorescein Diacetate), cell tracker green dye 
(MW 464.86). This dye has absorption at 492 nm wavelength and emission at 517 nm. 
The dye was used at a final concentration of 0.5-25 µM (1:5000) in starvation medium. 
Cells were incubated with dye for 30 minutes and later the medium was removed. This 
was replaced then with starvation medium without the dye and incubated for another 30 
minutes. Later, a uniform wound was made on monolayer of cells using Beckman 
Coulter robot. The medium of cells was then changed back to full growth media. 
Olympus ScanR high-content microscope was then used to take pictures of cells before 
they started migrating. Cells were then allowed to migrate for 14 hours in presence of 
EGF present in full growth media and images were taken using Olympus ScanR high-
content microscope. The average distance migrated (A.M.D) by the cells was then 
calculated using qCMA software [110]. 
 
2.2.11. Patient Data Analysis 
Breast cancer patient dataset analysis was performed by Ashwini Kumar Sharma from 
the Division of Theoretical Bioinformatics, DKFZ. Normalized mRNA and miRNA 
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expression data from the METABRIC study [106, 111] was used to analyze differential 
expression of target genes in ER subgroups. To investigate this, dataset consisting of 
781 patients whose ER status was known and who had both mRNA and corresponding 
miRNA expression data available (N = 781) was analyzed. Welch’s t-test was 
performed to detect significant differential expression changes between the two ER 
subgroups. MiRNA expression levels were categorized based on distribution quartiles 
into low (<Q1), medium (Q1-Q3) and high (>Q3) expression group. To evaluate 
association between mRNA and miRNA, a linear regression analysis was performed on 
scale normalized miRNA and mRNA expression data according to Spearman rank 
correlation. Fisher’s exact test was used to test association between miRNA groups and 
categorical clinico-pathological factors. Kruskal-Wallis test was used to test association 
between miRNA groups and quantitative clinico-pathological factors. For outcome 
analysis, disease-specific survival (DSS) was analysed as in [106], with disease-
unrelated deaths being censored. Univariate and multivariate Cox regression was used 
to assess the prognostic impact of miRNA expression levels and clinico-pathological 
factors for DSS. This analysis was performed by Thomas Hielscher from the Division 
of Biostatistics, DKFZ. Survival analysis was done using R package, from CRAN 
(http://CRAN.R-project.org/package=survival). All analyses were carried out using 
software R 3.0.1 (http://www.R-project.org) or GraphPad Prism 5.0 software. All t tests 
were two-sided tests. P-values below 0.05 are considered statistically significant.  
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3. Results 
3.1. miR-30c-2-3p negatively regulates NF-κB signaling and is down-
regulated in ER negative breast cancer patients 
A genome wide miRNA screen had been carried out previously to identify novel 
miRNA regulators of NF-κB signaling [103]. This screen had been based on a NF-κB 
reporter construct with three binding sites for NF-κB cloned in the promoter upstream 
of the luciferase ORF [103]. miRNA mimics were individually co-transfected with the 
NF-κB reporter construct together with β-galactosidase vector into HEK293FT cells. At 
48 hours after transfection, cells were treated with TNF-α for 5 hours to stimulate NF-
κB signaling, luminescence was then quantified. β-galactosidase was used for 
normalization of luciferase signal. In this screen, miR-30c-2-3p was as the third 
strongest negative regulator of the signaling pathway with a z-score of -2.031 among 
the 810 miRNAs screened (Figure 5A). To validate the result from screening, I repeated 
the NF-κB luciferase reporter assay again in the HEK293FT cell line and found that 
miR-30c-2-3p overexpression reproducibly abrogated NF-κB activity, which was 
similar to RNAi induced knockdown of RelA which was used as a positive control 
(Figure 5B). To study the role of miR-30c-2-3p in NF-κB regulation in the context of 
breast cancer, I next overexpressed the miRNA in the MDA-MB-231 cell line, an 
established model for ER- breast cancer [112]. miR-30c-2-3p overexpression decreased 
phosphorylation of NF-κB1 precursor compared to mimic control upon TNF-α 
stimulation, proving that indeed miR-30c-2-3p inhibited activation of NF-κB signaling 
also in the context of breast cancer (Figure 5C). 
 
To ascertain the role of miR-30c-2-3p in breast cancer patients, I next investigated 
whether endogenous expression levels of miR-30c-2-3p were associated with the ER 
status of patients, since NF-κB signaling is known to be constitutively active in ER 
negative breast cancer tumors [44, 46]. To investigate this, dataset from the 
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study 
was analyzed, which has miRNA expression data from a cohort of 781 breast tumors 
[106]. This analysis identified miR-30c-2-3p as a significantly downregulated miRNAs 
in ER negative versus ER positive breast cancer patients (Figure 5D and E). The same 
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relation between miR-30c-2-3p expression and ER status was verified (Figure 6A) in an 
independent cohort of 432 breast tumors from The Cancer Genome Atlas (TCGA) [6]. 
This was further validated in vitro in a panel of seven breast epithelial cell lines where 
the endogenous expression of miR-30c-2-3p was lower in ER negative compared to ER 
positive cell lines (Figure 6B). However, from cell line data only a trend was observed 
(P = 0.057). 
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 Figure 5: miR-30c-2-3p regulates NF-κB signaling in breast cancer. (A) z-score distribution of 810 
miRNAs screened for effects on NF-κB signaling based on 3xKBL luciferase assay where miR-30c-2-
3p was the third strongest negative regulator with a z-score of -2.031 [103]. (B) Validation of the 
screen results where miR-30c-2-3p strongly reduced the luciferase signal in HEK293FT cell line to 
measure NF-κB activity upon stimulation of the signaling by TNF-α (20  ng/ml). β-galactosidase was 
used for normalization. siRELA was used as a positive control (***p≤0.001 compared to respective 
stimulated control, t test). Data are shown as mean±s.d of two biological and three technical replicates. 
(C) phospho-NF-κB1 protein levels are downregulated upon treatment of MDA-MB-231 with 20  
ng/ml of TNF-α for 10 minutes in cells transfected with miR-30c-2-3p mimic compared to mimic 
CTRL. Cells were harvested 48h after transfection. Actin was used as a loading control. (D) Volcano 
plot showing miR-30c-2-3p as one of the most deregulated miRNA based on the fold change and q 
value (P value corrected for multiple testing, Benjamini-Hochberg) out of the 853 miRNAs analyzed 
in the METABRIC study [106]. Black dots represent significant genes miRNA and gray dots represent 
insignificant and low variance miRNAs. (E) miR-30c-2-3p was downregulated in ER negative 
compared to ER positive breast cancer patients in the METABRIC dataset [106] (P = 3.3e-34).  
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Figure 6: Expression levels of miR-30c-2-3p in an independent breast cancer patient dataset and breast 
epithelial cell lines. (A) miR-30c-2-3p was found to be lower expressed in ER negative compared to ER 
positive breast cancer patients (P = 0.0124) in TCGA study [6]. (B) Validation of miR-30c-2-3p expression in 
a panel of seven breast epithelial cell lines. The expression of miR-30c-2-3p showed a trend of higher level in 
ER positive compare to ER negative breast cell lines (P = 0.057). Data are shown as mean±s.d of two 
biological and three technical replicates. 
 
 
3.2. Expression of miR-30c-2-3p significantly correlates with clinico-
pathological features in breast cancer patients 
Since miR-30c-2-3p is significantly associated with the ER status in breast cancer, I 
hypothesized that its expression might also correlate with additional clinico- 
pathological parameters in patients like tumor grade, tumor size, age at diagnosis, 
lymph node invasion, HER2 expression, progesterone receptor (PR) status and TP53 
status. To test this hypothesis, the METABRIC dataset [106] was analyzed by Thomas 
Hielscher from the Division of Biostatistics, DKFZ.  
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To investigate this, miRNA expression levels were categorized based on distribution 
quartiles into low (<Q1), medium (Q1-Q3) and high (>Q3) expression groups of 
patients. These groups were then tested for association between miRNA groups and 
categorical clinico-pathological factors. Indeed, a significant correlation between low 
expression levels of miR-30c-2-3p and the presence of adverse prognostic factors was 
found (Table 21). Furthermore, disease-specific survival was significantly better in 
patients with medium (HR = 0.64, P = 0.005) and high (HR = 0.43, P<0.0001) miR-
30c-2-3p expression levels in univariate analysis (Table 22). However in multivariate 
analysis, miR-30c-2-3p expression did not remain an independent prognostic factor of 
disease specific survival in breast cancer patients (Table 22). 
 
 
Table 21: Association of miR-30c-2-3p expression with clinico-pathological 
features in breast cancer patients. Breast cancer patient data from METABRIC 
study [106]. 
 
  
  Parameter P value 
1 Tumor grade < 1e-04 
2 Tumor size 0.01910 
3 Age at diagnosis < 1e-04 
4 Lymph nodes positive < 1e-04 
5 ER < 1e-04 
6 HER2 < 1e-04 
7 PR < 1e-04 
8 TP53 mutation status < 1e-04 
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Table 22: Univariate and multivariate Cox proportional hazard regression analysis 
in breast cancer patients to evaluate prognostic impact of miR-30c-2-3p 
expression. Breast cancer patient data from METABRIC study [106]. 
ref: Reference, HR: Hazard ratio, LCL: Lower confidence limit, UCL: Upper confidence limit, low , mid 
and high levels refers to the expression level of miR based on distribution quartile, tumor grade 1, 2 , 3 
refers to differentiation status, +/- indicate presence or absence of receptor, WT: wild type, MUT: 
mutated type. 
 
  
 covariate  level ref HR LCL UCL P value HR LCL UCL P value 
1.  
  
miR-30c-2-
3p 
expression 
in 3 groups  
mid low 0.64 0.46 0.87 0.00505 0.97 0.65 1.45 0.89594 
high low 0.43 0.28 0.66 < 1e-04 0.84 0.49 1.45 0.53023 
 
2.  
  
Tumor 
grade  
2 1 1.10 0.53 2.32 0.79486 0.99 0.42 2.35 0.97807 
3 1 2.44 1.19 4.98 0.01451 1.57 0.66 3.71 0.30951 
3.  Tumor size   1.02 1.02 1.03 < 1e-04 1.01 1.00 1.02 0.00805 
4. Age at 
diagnosis  
  1.00 0.98 1.01 0.42995 1.00 0.99 1.02 0.74225 
5.  Lymph 
nodes 
positive  
  1.11 1.08 1.14 < 1e-04 1.07 1.04 1.11 < 1e-04 
6.  ER + - 0.44 0.32 0.60 < 1e-04 0.75 0.47 1.21 0.24080 
7.  HER2 + - 2.50 1.74 3.58 < 1e-04 1.80 1.18 2.76 0.00632 
8.  PR + - 0.49 0.37 0.65 < 1e-04 0.87 0.58 1.30 0.49510 
9.  TP53 
mutation 
status  
WT MUT 0.35 0.24 0.51 < 1e-04 0.50 0.33 0.75 0.00098 
Univariate analysis 
 
 
Multivariate analysis 
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3.3. Ectopic expression of miR-30c-2-3p reduces expression of genes 
relevant in inflammation, decreases cell proliferation, and 
invasion/migration  
To investigate the role of miR-30c-2-3p in the regulation of NF-κB signaling, I 
evaluated the expression of NF-κB targets genes in response to TNF-α stimulation in 
miR-30c-2-3p transfected MDA-MB-231 cells. Expression of proinflammatory 
cytokines IL8, IL6, and CXCL1 was strongly downregulated in cells transfected with 
miR-30c-2-3p compared to mimic control transfected cells upon induction of signaling 
with TNF-α (Figure 7A). Next, I checked expression of MYC, CCND1 and CSF2 which 
are also known NF-κB transcriptional targets involved in promoting cell proliferation 
[48, 113, 114]. Indeed, qRT-PCR showed that these genes were significantly reduced in 
miR-30c-2-3p over-expressing cells (Figure 7B). To test the effects of miR-30c-2-3p 
overexpression on basal level of cell proliferation, I performed cell proliferation assays 
in absence of any stimulation. This showed that miR-30c-2-3p significantly decreased 
cell proliferation in MDA-MB-231 cells (Figure 7C). Finally, to study the effects on cell 
cycle progression, I performed BrdU and 7-AAD staining on miR-30c-2-3p and mimic 
control transfected cells. Overexpression of miR-30c-2-3p significantly blocked cell 
cycle progression in MDA-MB-231 cells with only 2.65(+/-0.73) % cells in S-phase of 
cell cycle compared to 17.10(+/-2.6) % in the control (Figure 7D).  
 
Since NF-κB signaling also positively regulates cell invasion, and MDA-MB-231 is a 
highly invasive cell line [115], I wanted to investigate if miR-30c-2-3p was also capable 
of abrogating cell invasion. Indeed, a decreased invasive capacity of MDA-MB-231 
cells was observed upon miR-30c-2-3p overexpression as measured in Real Time Cell 
Analyzer (RTCA) (Figure 7E). Since NF-κB signaling has previously been shown to 
facilitate cell invasion/migration through the regulation of metalloproteinases (MMPs), 
like MMP-9 [116], I hypothesized that decreased invasion might be accompanied by 
decreased MMP-9 levels upon miR-30c-2-3p overexpression. Indeed, downregulation 
of MMP-9 was observed at the mRNA level in the presence of miR-30c-2-3p upon 
TNF-α stimulation (Figure 7F).  
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Figure 7: Effect of miR-30c-2-3p overexpression on expression of cytokines, cell proliferation and 
cell invasion in MDA-MB-231 breast cancer cell line. (A) mRNA expression of inflammatory cytokines 
IL8, IL6 and CXCL1 is reduced upon miR-30c-2-3p overexpression. To activate NF-κB signaling, cells 
were treated with TNF-α (20  ng/ml) for 5 hours before being harvested. (***p≤0.001 compared to 
stimulated control, t test). (B) In the same experimental setup, reduced mRNA levels of proliferation 
related genes MYC, CCND1 and CSF2 was observed (***p≤0.001, **p≤0.01 compared to stimulated 
control, t test). (C) miR-30c-2-3p reduced cell viability compared to mimic CTRL measured 72 hours after 
transfection. (**p≤0.01 compared to control, t test). (D) 7-AAD and BrdU staining was measured 72 hours 
after transfection with mimic CTRL or miR-30c-2-3p to measure cell cycle phases. A reduced S-phase 
population, gated for BrdU positive cells was observed upon miR-30c-2-3p overexpression (***p≤0.001 
compared to control, t test). (E) miR-30c-2-3p reduced the invading capability of MDA-MB-231 cells. 
Significance was tested at the 15 hour time point measured in Real-Time Cell Analyzer (RTCA), which 
was 48 hours after transfection with miRNA (***p≤0.001 compared to control, t test). (F) Concordantly, 
reduced level of mRNA level of MMP-9 by miR-30c-2-3p upon TNF-α (20  ng/ml) treatment of cells for 5 
hours to activate the signaling. Cells were harvested 48 hours after transfection with miRNA (***p≤0.001 
compared to stimulated control, t test). Data are shown as mean±s.d of two biological and three technical 
replicates. 
 
 
 
 
 
 
 
 
57 
To further study the effect on cell proliferation, I did direct cell counting of cells after 
transfection of MDA-MB-231 cells with mimic control or miR-30c-2-3p. After 72 
hours of transfection, miR-30c-2-3p overexpressing cells were fewer in number as seen 
in bright field microscope (Figure 8A). When cells were counted and analyzed after 
Hoechst staining in Olympus ScanR microscope, the cell number was significantly 
reduced compared to mimic control transfected cells (Figure 8B). 
 
Next, I wanted to investigate if miR-30c-2-3p is capable of inducing apoptosis in cells. 
To this effect, I measured the caspase 3/7 activity in cells transfected with miR-30c-2-
3p or mimic control. MDA-MB-231 cells overexpressing miR-30c-2-3p had higher 
caspase3/7 activity, 72 hours post transfection (Figure 8C). These effects on 
proliferation and apoptosis were independently verified in another the ER negative 
breast cell line, MCF10A (Figure 9A and B). 
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Figure 8: miR-30c-2-3p overexpression reduced cell number and increased apoptosis in MDA-MB-
231 cells. (A) MDA-MB-231 cells were seeded in 96-well glass bottom plates and transfected with miR-
30c-2-3p or mimic CTRL. After 72 hours of transfection, miR-30c-2-3p transfected cells were more round 
in shape and fewer cell were attached to the surface compared to mimic control transfected cells. Images 
were taken at 10x magnification with bright field microscope. (B) For quantification cells were stained 
with Hoechst dye and counted using Olympus ScanR microscope. miR-30c-2-3p overexpressing cells were 
significantly reduced compared to the control (***p≤0.001 compared to control, t test). (C) miR-30c-2-3p 
increases apoptosis compared to mimic control in MDA-MB-231 cell line 72 hours after transfection 
(***p≤0.001 compared to control, t test). Data are shown as mean from two biological and three technical 
replicates ±s.d. 
Figure 9: Effects of miR-30c-2-3p overexpression in MCF-10A cells. (A) Decreased cell viability (B) 
and increased apoptosis in MCF-10A was observed compared to mimic CTRL, 72 hours after 
transfection. (***p≤0.001 compared to control, t test). Data are shown as mean from two biological and 
three technical replicates ±s.d. 
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To study the effect of miR-30c-2-3p on cell migration, I used MCF-10A as the cell line 
system because it is a non-tumorigenic breast epithelial cell line, with strong migration 
ability in response to EGF and the ability to form an epithelial sheet when confluent 
[117]. This confluent sheet can be scratched and used to study cell migration using a 
scratch-wound assay (Figure 10). This assay is well recognized for measuring epithelial 
cell motility [118]. For evaluating the Average Migratory Distance (A.M.D) covered by 
the cells during the migration assay, generic merge software program was used [110]. 
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Figure 10: miR-30c-2-3p is an inhibitor of migration in MCF-10A cell line.  An artificial wound was 
introduced on monolayer of cells 48 hours after transfection with (A) negative (non-targeting controls) 
(B) positive controls (siEGFR) and (C) miR-30c-2-3p. Cells were then induced to migrate with full 
growth media containing 20 ng/ml of EGF. The average distance migrated by the cells was then 
calculated 14 hours post EGF stimulation. Data are shown as mean from two biological and three 
technical replicates ±s.d. 
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Figure 11: Quantification of MCF-10 A cell migration upon miR-30c-2-3p overexpression. Cell 
migration was significantly reduced upon miR-30c-2-3p overexpression in response to EGF. Data 
are shown as mean from two biological and three technical replicates ±s.d. 
 
miR-30c-2-3p transfected cells showed reduced migratory capability in response to 
EGF (Figure 10) compared to control transfected cells. Upon quantification of the 
distance migrated by cells, miR-30c-2-3p transfected cells had 60% lower migratory 
ability compared to control transfected cells (Figure 11). siEGFR was used as a positive 
control for the experiments. 
 
3.4. miR-30c-2-3p directly targets TRADD 
Next, I wanted to uncover the molecular mechanism of regulation by miR-30c-2-3p to 
explain the different observed phenotypes in breast cancer cells. To this end, I 
performed a whole transcriptome mRNA expression analysis of MDA-MB-231 cells 
transfected with miR-30c-2-3p compared to cells transfected with mimic control. 
Ectopic expression of miR-30c-2-3p resulted in 38 fold higher expression of this 
miRNA (Supplementary figure 1) and to a distinctly different gene expression profile 
compared to mimic control transfected cells (Figure 12). Bioinformatic analysis 
performed by Ashwini Kumar Sharma identified 370 genes (given in Supplementary 
table 1) which were downregulated at the mRNA level upon miR-30c-2-3p 
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overexpression with a corrected P value of less than 0.05. This approach can identify 
mRNA targets affected at post transcriptional level by miRNA. However targets 
affected on protein level or post translational level cannot be identified by this approach.  
 
 
 
 
 
  
Figure 12: Dendogram showing clustered gene expression analysis. MDA-MB-231 cells were 
transfected with miR-30c-2-3p or mimic control. Cells were harvested 48 hours after transfection. Gene 
expression profiling data revealed 370 genes that are downregulated at mRNA level upon miR-30c-2-3p 
overexpression. Figure is representative of 3 biological replicates represented by A, B & C.   
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To identify potential target genes of miR-30c-2-3p within the NF-κB signaling pathway, 
I intersected these 370 genes with a list of NF-κB related genes (obtained from KEGG 
pathway database, http://www.genome.jp/kegg/pathway.html). This analysis identified 
TRADD as a potential target gene which is involved in TNF-α induced NF-κB 
activation. Gene Ontology (GO) term analysis identified biological processes in which 
TRADD is involved, including NF-κB signaling activation (Table 23). To explore the 
possibility of TRADD as a direct target, I verified the result from gene expression 
analysis using qRT-PCR taqman which showed that the mRNA level of TRADD was 
significantly reduced upon miR-30c-2-3p overexpression compared to mimic control 
transfected cells (Figure 13A). In silico analysis using miRWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/) revealed that TRADD is also a predicted target of 
miR-30c-2-3p (Figure 13B) with one putative target site in the 3´UTR. Immunoblotting 
revealed the same downregulation at the protein level (Figure 13C). 
 
To prove direct targeting of TRADD by miR-30c-2-3p, I cloned the wild type 3´UTR of 
TRADD, or the mutant version containing four point mutations within the miRNA 
target site downstream of the Renilla luciferase open reading frame, in the dual 
luciferase vector psiCHECK2. A significant down regulation of Renilla luciferase signal 
in the presence of miR-30c-2-3p compared to mimic control was observed when using 
the wild type 3´UTR of TRADD in the MDA-MB-231 cell line. In contrast, this effect 
was abrogated when the mutated 3´UTR vector was used (Figure 13D). These results 
put together suggested that TRADD is a direct target of miR-30c-2-3p. For further 
validation, METABRIC data was analyzed [106, 111] to establish a correlation between 
mRNA of TRADD and miR-30c-2-3p expression in patients. Indeed, a significant anti-
correlation (P = 0.03) in patients was found (Figure 13E) revealing the pathological 
significance of targeting that I initially discovered in vitro.  
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Table 23: GO term analysis for biological processes regulated by TRADD. 
GO_id Term 
GO:0051291 protein heterooligomerization 
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of 
ligand 
GO:0035666 TRIF-dependent toll-like receptor signaling pathway 
GO:0002756 MyD88-independent toll-like receptor signaling pathway 
GO:0034138 toll-like receptor 3 signaling pathway 
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling 
GO:0033209 tumor necrosis factor-mediated signaling pathway 
GO:0034142 toll-like receptor 4 signaling pathway 
GO:0034612 response to tumor necrosis factor 
GO:0006915 apoptotic process 
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling 
GO:0045651 positive regulation of macrophage differentiation 
GO:0051259 protein oligomerization 
GO:2000116 regulation of cysteine-type endopeptidase activity 
GO:0006461 protein complex assembly 
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Figure 13: TRADD is a direct target of miR-30c-2-3p: (A) Downregulation of TRADD at mRNA upon 
miR-30c-2-3p overexpression 48 hours after transfection with miRNA (**p≤0.01 compared to control, t 
test). (B) Alignment of miR-30c-2-3p with target site within TRADD 3´UTR. (C) Downregulation of 
TRADD protein level upon overexpression of miR-30c-2-3p compared to mimic CTRL 48 hours after 
transfection with miRNA. Actin was used as a loading control. (D) Reduced Renilla luciferase signal in 
cells transfected with 3´UTR of TRADD and miR-30c-2-3p compared to mimic CTRL 48 hours after 
transfection with miRNA (**p≤0.01 compared to control, t test). This effect was lost when the binding 
site in 3´UTR was mutated. Renilla luciferase values were normalized to an internal firefly luciferase 
control and the values reported as fold expression compared to mimic control. Data are shown as 
mean±s.d of two independent biological and three technical replicates. (E) A negative correlation (based 
on Spearman rank correlation) between scale normalized miR-30c-2-3p and TRADD mRNA levels is 
seen in breast cancer patients (N = 781) from the METABRIC study [106, 111].  
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3.5. TRADD regulates NF-κB signaling in breast cancer cells 
To assess the influence of TRADD on NF-κB signaling and to investigate if TRADD as 
a target can explain the effects caused by miR-30c-2-3p, I used siRNA to knockdown 
TRADD expression in MDA-MB-231 cells. Knockdown of TRADD by siRNA was 
confirmed both at mRNA and protein levels (Figure 14 A and B). To study the effect of 
TRADD knockdown on NF-κB signaling, I repeated the NF-κB reporter assay after 
TRADD knockdown to assess the effect on NF-κB signaling activation. Indeed, the 
knockdown of TRADD reduced NF-κB signaling despite TNF-α stimulation (Figure 
15A) at a level similar to that of elevated miR-30c-2-3p (Figure 5B). Next, I evaluated 
the effects on expression of inflammatory cytokines. Similar to effects seen upon 
overexpression of miR-30c-2-3p, proinflammatory cytokines like IL8, IL6 and CXCL1 
were down regulated upon TRADD inhibition in MDA-MB-231 cells at mRNA level 
(Figure 15B). Further, both overexpressing miR-30c-2-3p and inhibiting TRADD 
reduced the phosphorylation of NF-κB precursor (p105) upon stimulation with TNF-α 
(Figure 15C). The precursor p105 is processed to p50 which can act in the nucleus as 
homodimers or heterodimers along with p65 and c-Rel to regulate gene expression 
[119].  
Figure 14: TRADD knockdown efficiency with siTRADD in the MDA-MB-231 cell line. (A) 
Significantly reduced expression was seen at the mRNA level 48 hours after transfection (***p≤ 0.001 
compared to control, t test). Data are shown as mean±s.d of two biological and three technical replicates. 
(B) Protein level of TRADD was similarly reduced by siTRADD. Actin was stained as a loading control. 
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To ascertain the effect of TRADD on proliferative capability, I performed 7-AAD and 
BrdU staining of MDA-MB-231 cells transfected with siTRADD or non targeting 
control. However, unlike miR-30c-2-3p, TRADD knockdown only mildly reduced S-
phase of the cell cycle (Figure 15D). Next, I checked the role of TRADD knockdown on 
the invasive capability of MDA-MB-231 cells. Indeed, similar to miR-30c-2-3p 
overexpression, TRADD knockdown significantly blocked cell invasion (Figure 15E) 
and reduced MMP-9 mRNA levels upon TNF-α stimulation (Figure 15F). To further 
investigate the effect of ectopic expression of miR-30c-2-3p as well as of TRADD 
knockdown on NF-κB signaling activation by TNF-α, I checked the phosphorylation of 
levels IKKα/IKKβ (important kinases of the pathway). Indeed, in both cases, a decrease 
in phosphorylation levels were observed compared to stimulated non targeting controls 
(Figure 16). This observation provided further evidence for the regulation of NF-κB 
signaling by miR-30c-2-3p through TRADD targeting. 
 
These results suggested that TRADD, as a direct target, was only able to phenocopy the 
effects of miR-30c-2-3p on NF-κB signaling. The effects on cell proliferation were not 
completely phenocopied by TRADD, indicating that there are additional targets of miR-
30c-2-3p. 
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Figure 15: miR-30c-2-3p regulates NF-kB signaling by TRADD targeting. (A) Downregulation of 
TRADD with siRNA significantly decreased the luciferase signal measuring NF-κB activity upon 
activation of signaling with TNF-α (20  ng/ml) for 5 hours. This was similar to reduction seen upon miR-
30c-2-3p overexpression (***p≤0.001 compared to stimulated control, t test). (B) mRNA expression of 
proinflammatory cytokines IL-8, IL-6 and CXCL-1 was reduced upon TRADD knockdown and activation 
of signaling with TNF-α (cells treated for 5 hours) (***p≤0.001, **p≤0.01,*p≤0.05 compared to 
stimulated control, t test). (C) Reduced phospho NFκB1 protein levels were observed upon treatment with 
20  ng/ml TNF-α for 10 min after 48 hours of transfection with miR-30c-2-3p or siTRADD compared to 
controls. No change in total protein level was seen. GAPDH was used as a loading control. (D) 
Knockdown of TRADD did not have a significant effect on S-phase of the cell cycle compared to control, 
72 hours after transfection. (E) siTRADD reduced invasion in the highly invasive MDA-MB-231 breast 
cell line (***p≤0.001 compared to control, t test). (F) In addition, siTRADD reduced MMP-9 at the 
mRNA levels after treatment of cells with TNF-α (20  ng/ml) for 5 hours after 48 hours of transfection. 
(*p≤0.05 compared to control, t test). Data are shown as mean±s.d of two biological and three technical 
replicates. 
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Figure 16: Effect of miR-30c-2-3p ectopic expression and TRADD knockdown on activation of NF-
κB signaling. Reduced phospho-IKKα (Ser176)/IKKβ (Ser177) protein levels were observed upon 
treatment with 20  ng/ml of TNF-α for 10 minutes after 48 hours of transfection with miR-30c-2-3p or 
siTRADD compared to controls. No change in total protein level was seen. GAPDH was used as a 
loading control. 
 
To study the effect of TRADD knockdown on expression of genes involved in cell 
proliferation like MYC, CCND1 and CSF2, I performed qRT-PCR to quantify the 
mRNA changes in MDA-MB-231 cells stimulated with TNF-α. TRADD knockdown 
downregulated CSF2 significantly upon TNF-α stimulation (Figure 17). However, 
expression of MYC and CCND1 was slightly but not significantly upregulated in the 
same experimental setup (Figure 17). 
Figure 17: Effect of TRADD knockdown on expression of proliferation genes TRADD knockdown 
did not reduce mRNA expression of MYC and CCND1 upon treatment of MDA-MB-231 cells with TNF-
α (20  ng/ml) for 5 hours. However, a significant reduction in mRNA levels of CSF2 was observed. All 
experiments were made 48 hours after transfection. (***p≤0.001 compared to stimulated control, t test). 
Data are shown as mean±s.d of two biological and three technical replicates. 
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I next tested the effect of miR-30c-2-3p overexpression or TRADD knockdown on NF-
κB activation using lipopolysaccharide (LPS) to stimulate NF-κB signaling instead of 
TNF-α. To investigate this, I again performed the 3xKBL luciferase assay. NF-κB 
activation was similarly reduced (Figure 18) as after TNF-α stimulation, underlining the 
role of TRADD and miR-30c-2-3p in regulation of canonical NF-κB signaling. 
 
3.6. miR-30c-2-3p regulates cell cycle progression by directly targeting 
CCNE1 
To further investigate the potential target genes which are responsible for the observed 
reduction in S-phase of the cell cycle, I performed pathway enrichment analysis on the 
mRNAs that are downregulated upon miR-30c-2-3p overexpression using MetaCore™ 
(http://thomsonreuters.com/metacore/). This identified the most deregulated signaling 
pathways upon miR-30c-2-3p overexpression (Table 24).  
  
Figure 18: Effect of TRADD knockdown or miR-30c-2-3p overexpression on LPS induced NF-κB 
activation.  RelA and TRADD knockdown as well as miR-30c-2-3p overexpression inhibited LPS induced 
NF-κB activation measured with NF-κB reporter plasmid in HEK293FT cell line (***p≤0.001, **p≤0.01 
compared to stimulated control, t test). Cells were treated with 10 ng/ml of LPS for 5 hours. Data are shown 
as mean±s.d of two biological and three technical replicates. 
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Table 24: Top 10 significantly downregulated pathways from Metacore pathway 
enrichment analysis upon miR-30c-2-3p overexpression.  
FDR: False discovery rate 
 
  
 Signaling Pathways Total 
genes 
P value FDR Genes 
in data 
1. Cell cycle: Start of DNA replication 
in early S-phase 
32 8.745E-07 3.682E-04 7 
2. Cell cycle: Role of SCF complex in 
cell cycle regulation 
29 7.772E-06 1.636E-03 6 
3. Cell cycle: Influence of Ras and 
Rho proteins on G1/S Transition 
53 2.680E-04 3.671E-02 6 
4. Cell cycle 21 3.924E-04 3.671E-02 4 
5. Cell cycle: Regulation of G1/S 
transition  
38 4.360E-04 3.671E-02 5 
6. Cytoskeleton remodelling: Role of 
PDGFs in cell migration 
24 6.695E-04 4.698E-02 4 
7. Transcription: Androgen Receptor 
nuclear signaling 
45 9.642E-04 5.723E-02 5 
8. Glutathione metabolism / Rodent 
version 
70 1.206E-03 5.723E-02 6 
9. Cell cycle: Transition and 
termination of DNA replication 
28 1.223E-03 5.723E-02 4 
10. Some pathways of EMT in cancer 
cells 
51 1.708E-03 7.190E-02 5 
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In line with the effects shown by miR-30c-2-3p on inhibition of cell proliferation, 
pathways involved in cell cycle regulation were highly enriched upon miR-30c-2-3p 
overexpression. Cyclin E1 (CCNE1), a cell cycle regulatory protein involved in G1 to S 
transition [120] and frequently overexpressed in breast cancer [121], was down 
regulated at the mRNA level (Figure 19A) and also a predicted target of miR-30c-2-3p 
(Figure 19B) by miRWalk. Down regulation of CCNE1 at the protein level upon miR-
30c-2-3p overexpression was confirmed using immunoblotting (Figure 19C). In 
summary, CCNE1 (known oncogene in breast cancer) was downregulated both at the 
mRNA and protein levels upon ectopic over-expression of miR-30c-2-3p. 
  
Figure 19: miR-30c-2-3p directly targets CCNE1. (A) mRNA levels of CCNE1 are significantly 
downregulated upon miR-30c-2-3p overexpression 48 hours after transfection with miRNA (***p≤0.001 
compared to control, t test). Data are shown as mean±s.d of two biological and three technical replicates.. 
(B) CCNE1 is a predicted target of miR-30c-2-3p. (C) miR-30c-2-3p reduced CCNE1 at protein level 
compared to control. Actin was used a loading control. 
 
73 
Gene Ontology (GO) term analysis identified biological processes in which CCNE1 is 
involved (Table 25) that include regulation of cell cycle at G1 to S transition. 
 
Table 25: GO term analysis for biological processes regulated by CCNE1 
GO_id Term 
GO:0000082 G1/S transition of mitotic cell cycle 
GO:1901990 regulation of mitotic cell cycle phase transition 
GO:0010564 regulation of cell cycle process 
GO:1901987 regulation of cell cycle phase transition 
GO:0044772 mitotic cell cycle phase transition 
GO:0044770 cell cycle phase transition 
GO:0007093 mitotic cell cycle checkpoint 
GO:0007346 regulation of mitotic cell cycle 
GO:1901991 negative regulation of mitotic cell cycle phase transition 
GO:1901988 negative regulation of cell cycle phase transition 
GO:0000075 cell cycle checkpoint 
GO:0090068 positive regulation of cell cycle process 
GO:0051726 regulation of cell cycle 
GO:0072431 signal transduction involved in mitotic G1 DNA damage 
checkpoint 
GO:1902400 intracellular signal transduction involved in G1 DNA damage 
checkpoint 
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To study the effects of CCNE1 on cell cycle, I used siRNA against CCNE1 to block its 
expression. The efficiency of knockdown was confirmed both at mRNA and protein 
levels (Figure 20). Effect on cell cycle progression was then evaluated using 7-AAD 
and BrdU staining. As expected, CCNE1 knockdown phenocopied reduction in S-phase 
of cell cycle (Figure 21) that was also seen with miR-30c-2-3p overexpression (Figure 
7D). 
Figure 21: CCNE1 knockdown reduces the population of MDA-MB-231 cells in S-phase of cell cycle. 
Reduced S-phase population of MDA-MB-231 cells was seen 72 hours after transfection with siCCNE1 
(***p≤0.001 compared to control, t test). Data are shown as representative of two biological and three 
technical replicates. 
Figure 20: CCNE1 knockdown efficiency with siCCNE1 in the MDA-MB-231 cell line. (A) 
Significantly reduced expression of CCNE1 upon knockdown with siCCNE1 was seen at the mRNA 
level 48 hours after transfection (***p≤ 0.001 compared to control, t test). Data are shown as 
mean±s.d of two biological and three technical replicates. (B) Protein level of CCNE1 was similarly 
reduced by siCCNE1. Actin was used as a loading control. 
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Using a reporter gene construct, I confirmed direct targeting of CCNE1 by miR-30c-2-
3p (Figure 22A). Similar to the observations made for TRADD, the expression of 
CCNE1 and miR-30c-2-3p was significantly anticorrelated in the METABRIC cohort of 
breast cancer patients [106, 111] (Figure 22B), suggesting clinical relevance of this 
targeting. 
 
Figure 22: CCNE1 is a direct target of miR-30c-2-3p. (A) The luciferase assay with 3´UTR of CCNE1 
upon overexpression of miR-30c-2-3p showed a significant decrease in Renilla luciferase signal 
compared to mimic CTRL transfected cells. This effect was abolished when the miR-30c-2-3p seed 
region within the 3´UTR of CCNE1 was mutated. (***p≤0.001 compared to control, t test). Renilla 
luciferase values were normalized to an internal firefly luciferase control and the values reported as fold 
expression compared to mimic control. Data are shown as mean±s.d of two biological and three technical 
replicates. (B) A negative correlation (Spearman rank correlation) between scale normalized miR-30c-2-
3p and CCNE1 mRNA levels is seen in breast cancer patients (N = 781) from the METABRIC study 
[106, 111]. 
 
3.7. TRADD and CCNE1 are up regulated in ER negative breast 
cancer patients 
To further ascertain the relation between TRADD, CCNE1 and miR-30c-2-3p in breast 
cancer patients, the METABRIC data was analyzed [106, 111]. TRADD and CCNE1 
expression was found to be significantly up regulated (P<0.005) in ER negative patients 
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compared to ER positive breast cancer patients (Figure 23A and B), which corroborated 
with in vitro findings of my study. Next, the expression of miR-30c-2-3p was analyzed 
among the different subtypes of breast cancer in the METABRIC cohort of breast 
cancer patients [106]. In this dataset miR-30c-2-3p was found to be significantly lower 
expressed in basal-like and HER2 positive subtypes compared to the luminal subtypes 
(Figure. 23C). Finally, to assess the prognostic potential of miR-30-c-2-3p expression in 
patients, a survival analysis was performed. miR-30c-2-3p was found to be significantly 
associated with better survival in all three groups based on miRNA expression level 
distribution quartiles into low (<Q1), medium (Q1-Q3) and high (>Q3) expression 
groups (Figure 23D), further supporting a direct role in breast cancer and a tumor 
suppressive role for this miRNA. 
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Figure 23: Expression of TRADD, CCNE1 and miR-30c-2-3p in breast cancer patients. (A&B) The 
mRNA expression of both TRADD and CCNE1 is significantly higher in ER negative breast cancer 
patients [111]. (C) Across different molecular subtypes of breast cancer, the expression levels of miR-
30c-2-3p are lower in basal and HER2 enriched subtype [106]. (D) Higher expression of miR-30c-2-3p is 
associated with long term disease specific survival in patients for over 13 years [106]. 
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4. Discussion 
4.1. miR-30c-2-3p expression analysis in breast cancer patients  
To validate the expression of miR-30c-2-3p in breast cancer patients, RNA sequencing 
data from the TCGA (The Cancer Genome Atlas) study [6] and microarray gene 
expression data from the METABRIC (Molecular Taxonomy of Breast Cancer 
International Consortium) study [106] were analyzed. This was done to confirm 
expression levels of miR-30c-2-3p from independent platforms and two independent 
cohorts of breast cancer patients (Figure 5E and 6A). The two independent cohorts 
showed similar results for miR-30c-2-3p expression, with lower expression in ER- 
compared to ER+ breast cancer patients. This observation was recapitulated in vitro in a 
panel of 7 breast cell lines using miRNA qRT-PCR (Figure 6B). The validation for 
miRNA expression was critical in light of wrong miRNA annotations reported and to 
show that miR-30c-2-3p is a high confidence miRNA [96, 122]. miR-30c-2-3p has also 
been found in more than 2200 reads in miRBase (Version 21, accessed July 29, 2014) 
thus further supporting the relevance of this miRNA. 
 
4.2. miR-30c-2-3p mediated regulation of NF-κB signaling 
miRNAs are important regulators of gene expression during carcinogenesis, and the 
current project was aimed at elucidating the tumor suppressive activities of miR-30c-2-
3p in breast cancer patients. This established NF-κB signaling and cell cycle 
progression to be directly regulated by miR-30c-2-3p. These processes in turn regulate 
hallmarks of cancer like proliferation, invasion, and inflammation [65]. miR-30c-2-3p 
negatively regulates these phenotypes in breast cancer cells.  
 
The role of NF-κB signaling in cancer development and specifically in breast cancer 
progression is increasingly studied [28, 42, 43, 46, 123]. Constitutively active NF-κB 
signaling is detected both in mammary carcinoma cell lines and primary human breast 
cancer tissues [15]. It has also been implicated in development of resistance against 
anti-estrogen therapy e.g. tamoxifen with resistant cells expressing high levels of p50, 
RelB and increased phosphorylation of p65 [124]. Additionally, inhibiting NF-κB 
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signaling can re-sensitize these resistant cells to tamoxifen and could be expoited for the 
development of effective novel drugs for treatment of breast cancer patients [124]. This 
underlines the importance of studying constitutive activation of NF-κB signaling and 
effective ways to inhibit this in the context of breast cancer. 
 
The biological mechanisms of miRNAs to regulate or inhibit NF-κB signaling in breast 
cancer are currently being explored. The work by Kekikoglou et.al. on the miRNA-
520/373 family showed the negative regulation of NF-κB signaling by direct targeting 
of RelA in ER negative breast cancer patients [103]. Similarly, miR-31 has been shown 
to regulate NF-κB signaling by targeting protein kinase C epsilon and sensitizing human 
breast cells to apoptosis [104]. In the current study, TRADD was identified as a direct 
target gene of miR-30c-2-3p (Figure 13). TRADD is a member of tumor necrosis factor 
receptor superfamily characterized by the presence of a death domain (DD) and on the 
one hand, plays an important role in inducing proinflammatory responses by interacting 
with TNFR1 upon TNF-α activation [125]. On the other hand, TNFα can also initiate 
apoptosis and necrosis, through recruitment of another death domain containing protein 
known as FADD [126]. However, TNF-α induced NF-κB activation is attenuated in 
TRADD deficient cells as has been shown by somatic knockout of TRADD in a human 
B cell line [127], demonstrating the importance of TRADD in NF-κB signaling. These 
findings are further supported by results in TRADD deficient mice where TNF-α 
induced activation of NF-κB, ERK and JNK signaling has been found to be defective 
[128]. Upon TNF-α activation, TRADD interacts with other DD containing kinase 
protein like RIP1 (receptor-interacting protein-1) and the ubiquitin ligase, TRAF2 (TNF 
receptor–associated factor 2) [125]. These interactions ultimately activate signaling 
pathways like NF-κB and MAPK (Mitogen activated protein kinase) [125].  
 
This study confirmed that TRADD is required for TNF-α mediated activation of NF-κB 
signaling in breast cancer as well as its effect on expression of known NF-κB target 
genes like pro inflammatory cytokines IL8, IL6 and CXCL1 (Figure 15B). These 
cytokines contribute to the shaping of the tumor microenvironment by promoting 
inflammation in most solid tumors, including breast cancer [123, 129]. Other 
inflammation mediators part of the tumor microenvironment include chemokines and 
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prostaglandins [123]. All these mediators can then activate transcription factors, like 
NF-κB, in stromal cells and tumor cells which can in turn generate more inflammatory 
mediators and thus form an inflammatory microenvironment [123]. miR-30c-2-3p 
potently inhibited the expression of these inflammatory cytokines in MDA-MB-231 
cells (Figure 7A) suggesting that this miRNA could be a central factor in the regulation 
of tumor inflammatory processes that could be executed also via its direct target 
TRADD. Furthermore, TRADD knockdown inhibited the phosphorylation of NF-κB1 
and IKKα/IKKβ upon TNF-α stimulation, thus phenocopying the effect observed upon 
miR-30c-2-3p overexpression (Figure 15C and 16). Hence, miR-30c-2-3p inhibits 
activation of NF-κB signaling and as a result affects a number of downstream 
phenotypes. 
 
TRADD is also known to play a role in regulating TLR signaling by formation of a 
complex with TLR4 upon stimulation with TNF-α [128]. Moreover, TRADD deficiency 
inhibits cellular response like TNF-α production in response to LPS induction [128]. 
TLR signaling has been shown to support tumor growth by activating inflammatory 
response and supporting oncogenesis in the breast by activating NF-κB, MAPKs 
including JNK, p38 and ERK pathways [130]. These findings are in line with the results 
from my study showing that TRADD knockdown can inhibit LPS induced canonical 
NF-κB signaling and miR-30c-2-3p also shows this effect (Figure 18).  
 
TNF-α has been shown to have mitogenic function in breast cancer cells thereby 
promoting malignancy via NF-κB signaling activation [27, 28]. This finding is 
supported by in vitro data showing that TNF-α promotes proliferation in cancer cells 
(specifically breast cancer cells) [131] and in vivo data from experiments with murine 
breast cancer growth [28]. Interestingly, TNF-α is also a transcriptional target of NF-
κB. Activated signaling can thus lead to increased expression of TNF-α in a feed 
forward loop [123]. Moreover, TNF-α is known to promote tumor invasion by 
upregulating important extracellular matrix (ECM) degrading enzymes which are 
involved in metastasis and progression of a number of cancers [132]. Matrix 
metalloproteinases (MMPs), and specifically MMP-9 which has been shown to have 
potent basement degrading capability [133], was down regulated upon miR-30c-2-3p 
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overexpression (Figure 7E and F) as well as by knockdown of TRADD (Figure 15E and 
F). Taking these results together, the mode of regulation of NF-κB signaling by miR-
30c-2-3p can be well explained via TRADD targeting. Furthermore the anticorrelation 
between expression of TRADD mRNA and miR-30c-2-3p (Figure 13E) was also seen 
in the METABRIC cohort of breast cancer patients [106, 111]. 
 
 
In summary, TRADD can explain the effects of miR-30c-2-3p on phenotypes like 
cytokine expression and invasion that are regulated by NF-κB signaling (Figure 24). 
TRADD as a direct target however cannot explain the effects of miR-30c-2-3p on cell 
cycle inhibition. This can be explained by the ability of miRNAs to have multiple 
mRNA targets [98]. It was observed that, miR-30c-2-3p overexpression resulted in 
downregulation of 370 mRNAs. Pathway enrichment analysis on these mRNAs showed 
Figure 24: Molecular mechanism underlying the regulation of NF-κB signaling by miR-30c-2-3p in 
breast cancer cells. miR-30c-2-3p regulates invasion and cytokine expression by directly targeting 
TRADD. Idea of the figure adapted from [38]. 
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that miR-30c-2-3p downregulated key biological pathways related to cell proliferation 
(Table 24). miRNAs can therefore regulate many biological processes and have 
pleiotropic effects. 
 
4.3. Cell cycle inhibition by miR-30c-2-3p 
Cyclin E1 (CCNE1) was identified to be another direct target of miR-30c-2-3p (Figure 
19) which could explain the reduced proliferation capacity of breast cancer cells that 
was observed upon overexpression of this miRNA. CCNE1 interacts with cyclin 
dependent kinase CDK2 (Figure 25), and cell cycle inhibitors like CDKN1A, CDKN1B 
to regulate cell cycle. Both overexpression of miR-30c-2-3p (Figure 7D) or CCNE1 
knockdown (Figure 21) caused a decreased population of MDA-MB-231 cells in S-
phase of cell cycle. This effect was not seen upon knockdown of TRADD (Figure 15D), 
showing that miR-30c-2-3p regulates cell cycle progression and NF-κB signaling 
through targeting of different genes.  
 
Figure 25: miR-30c-2-3p inhibits cell cycle by directly targeting CCNE1 which is a central player of 
cell cycle network. CCNE1 regulates G1 restriction point (R) in cell cycle. By directly targeting CCNE1, 
miR-30c-2-3p inhibits cell proliferation in breast cancer cells. Idea of the figure adapted from [134]. 
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CCNE1 is a cell cycle regulatory protein that, along with CDK2, drives the cell cycle 
from G1 to S phase by CDK2 mediated phosphorylation of Rb protein and release of the 
transcription factor, E2F [120]. The complex of CCNE1 with CDK2 acts like a master 
switch for initiation of S-phase and the regulation of processes such as DNA synthesis, 
duplication of centrosome and chromatin assembly [58]. CCNE1 is frequently 
deregulated or undergoes gene amplification in breast cancer and higher expression is 
associated with poor overall survival compared to patients with lower expression [135].  
 
In the dataset published by the METABRIC study [106], CCNE1 was found to be 
upregulated in ER negative breast cancer patients compared to ER positive patients 
(Figure 23B). This is in line with the finding that miR-30c-2-3p is lower expressed in 
the ER negative group. Also, the expression of miR-30c-2-3p and CCNE1 is strongly 
anticorrelated (Figure 22B) in a cohort of 781 breast cancer patients [106, 111] showing 
the clinical relevance of the targeting by miR-30c-3p. 
 
The results found during my PhD work, are in line with a previous study on the tumor 
suppressive role of miR-30c-2-3p in ovarian cancer, where Jia and coworkers showed 
BCL9 as a direct target gene of the miRNA and proved its anti-proliferative effect 
[136]. Another report in clear cell renal cell carcinoma showed that lower expression of 
miR-30c-2-3p was associated with increased tumor growth through enhanced activity of 
hypoxia inducible factor (HIF2)α [137]. From the microarray gene expression data upon 
overexpression of miR-30c-2-3p, I observed that both BCL9 and HIF2α were not 
downregulated pointing towards tissue specific mode of regulation for this interaction. 
When the METABRIC data [106, 111] was analyzed to evaluate correlation between 
miR-30c-2-3p and BCL9 or HIF2α, it was found that there is a weak positive correlation 
between miR-30c-2-3p and BCL9 (Supplementary figure 2). However, in case of miR-
30c-2-3p and HIF2α a weak anti-correlation was observed (Supplementary figure 3). 
 
The precursor pre-miR-30c-2 is processed asymmetrically to form mature hsa-miR-30c-
5p (miR-30c) and hsa-miR-30c-2-3p (mir-30c-2*) from the 5´and 3´ arms of the 
precursor miRNA, respectively. miR-30c-5p has been shown to regulate 
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chemoresistance in breast tumors through direct targeting of the cytoskeleton gene 
TWF1 and indirect regulation of IL-11 [138]. In combination with my results this is an 
interesting finding as the two mature forms of the same precursor have different seed 
sequences and, therefore, different sets of target genes, but function as important 
regulators of gene expression in breast cancer. Both miRNAs appear to confer similar 
functions by the regulation of different target genes. A linear regression analysis 
identified the expression of miR-30-5p to be positively correlated to miR-30c-2-3p 
expression (Supplementary figure 4) in METABRIC study [106] emphasizing their co-
regulation and likely coordinated activities in breast cancer patients. However from the 
screening data for regulators of NF-κB signaling [103], miR-30c-2-3p had a strong 
negative effect on activation of NF-κB signaling (z score of -2.013) compared to the 
insignificant effect of miR-30c-5p (z-score of -0.258). 
 
In summary, miR-30c-2-3p affected key cellular phenotypes in breast cancer cells by 
regulating NF-κB signaling and cell cycle regulation. The effects on cell proliferation, 
invasion, migration and expression of inflammatory cytokines can be explained by 
CCNE1 and TRADD as direct targets in breast cancer. This molecular mechanism can 
be exploited to come up with better treatment options for ER negative as well as basal 
subtypes of breast cancer.  
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4.4. Conclusions and outlook 
Treatment of the basal-like subtype of breast cancer remains a big clinical challenge, 
with chemotherapy and radiation therapy in neoadjuvant therapy as the major options 
for treatment. Due to the lack of expression of ER, PR, HER2, or other targetable 
drivers of these tumors, no targeted therapies have been identified yet. This aggressive 
subtype of breast cancer is known to have aberrant NF-κB activation [139]. Effective 
inhibition of the aberrantly active NF-κB signaling cascade by targeted therapy in ER 
negative or basal-like tumors could be a solution to this problem. Initial efforts in this 
direction have already been made for the treatment of breast cancer [46]. miR-30c-2-3p 
was shown in this study to inhibit NF-κB signaling in case of ER negative breast cancer 
cells. Xenograft tumor mouse models, will allow testing of the efficacy of miR-30c-2-
3p to serve in cancer therapeutics.  
 
The property of miRNAs to inhibit a range of targets and affect signaling pathways is 
one way to overcome resistance caused by targeted or chemo therapies in cancer 
treatment. Moreover, tumors are associated with distinct expression patterns of miRNAs 
and mRNAs also known as expression signatures [140]. These can be used to study 
pathways which are deregulated specifically in cancer cells as opposed to the adjacent 
normal tissue. In the present study miR-30c-2-3p was shown to regulate two central 
pathways in breast cancer development, NF-κB signaling and cell cycle progression. 
However, there are a number of challenges that have to be tackled before miRNAs can 
potentially be used as effective therapeutic tools in treatment of cancer. These 
challenges include effective in vivo delivery, escape from enzymatic or blood clearance 
and off-targets repressed by miRNAs [141, 142]. Nevertheless, the future for miRNA in 
clinics as therapeutic drugs and as biomarkers to predict clinical outcomes looks 
promising with miR-34 mimic being tested in clinical trials for miRNA replacement 
therapy in cancer treatment because of its tumor suppressive role [143]. Another 
candidate, miR-122 inhibitor (also known as miravirsen) is in phase 2 clinical trials for 
the treatment of hepatitis C virus (HCV) infection [144]. In this case, locked nucleic 
acid (LNA) based oligonucleotides are used for targeting of endogenous expression of 
miR-122 [144]. 
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The work from my PhD study contributed to a novel understanding of miR-30c-2-3p 
mediated regulation in breast cancer by combining in vitro results with publically 
available breast cancer patients datasets that had long term follow up data of patients. 
This established miR-30c-2-3p as a tumor suppressor in breast cancer.  
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5. Own publications 
Publication No. 5 is about the work that I describe in the present thesis and is thus based 
mostly on my own work. I have described in the thesis where others have contributed. 
In all other publications, I contributed both scientifically and technically. This included 
discussion about respective projects and performing functional assays which contributed 
to the publication. 
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7. Supplementary data 
Supplementary Table 1: List of mRNAs downregulated upon miR-30c-2-3p 
overexpression. 
Entrez_Gene_ID Accession Symbol p_value BH 
3399 NM_002167.2 ID3 7.64765559133124e-07 0.01457613 
441518 NM_005532.3 IFI27 1.36042739467141e-06 0.01457613 
6746 NM_018660.2 ZNF395 1.78118271574823e-06 0.01457613 
8030 NM_173156.1 SMG7 2.0272781572215e-06 0.01457613 
9235 NM_178868.3 CMTM8 2.66415640914972e-06 0.01532422 
684 NM_080916.1 DGUOK 5.5325645082648e-06 0.01677677 
2181 NM_199069.1 NDUFAF3 5.57259508373374e-06 0.01677677 
51006 NM_018047.1 RBM22 6.88724576961158e-06 0.01677677 
152189 NM_001040455.1 SIDT2 6.93058005804733e-06 0.01677677 
4641 NM_024649.4 BBS1 7.44269022989081e-06 0.01677677 
55696 NM_181353.1 ID1 1.02771169643986e-05 0.01677677 
55893 NM_003145.3 SSR2 1.06702054063459e-05 0.01677677 
5296 NM_004124.2 GMFB 1.12435095670553e-05 0.01677677 
124565 NM_031899.2 GORASP1 1.16688276026016e-05 0.01677677 
10606 NM_001048201.1 UHRF1 1.20598314274373e-05 0.01677677 
85315 NM_032211.6 LOXL4 1.28364452562564e-05 0.01677677 
5147 NM_002601.2 PDE6D 1.33381160141058e-05 0.01677677 
723790 NM_004148.3 NINJ1 1.40000862614633e-05 0.01677677 
118460 NM_138357.1 CCDC109A 1.49218826909693e-05 0.01716613 
1525 NM_001080779.1 MYO1C 1.66997806924935e-05 0.017342 
9500 NM_014071.2 NCOA6 1.80366459547189e-05 0.017342 
3866 NM_024096.1 DCTPP1 1.80897081157651e-05 0.017342 
53371 NM_207309.1 UAP1L1 2.19462273625154e-05 0.01838882 
10668 NM_005334.2 HCFC1 2.36166602862947e-05 0.01838882 
244 NM_198120.1 EBAG9 2.42863391919032e-05 0.01838882 
7027 NM_031905.2 ARMC10 2.66987358277139e-05 0.01838882 
582 NM_003786.2 ABCC3 2.69212105359013e-05 0.01838882 
51090 NM_005937.3 MLLT6 2.71185849730176e-05 0.01838882 
8818 NM_003863.2 DPM2 2.89716965772341e-05 0.01838882 
3397 NM_001005332.1 MAGED1 2.97865042589916e-05 0.01838882 
8318 NM_004335.2 BST2 3.05238907860973e-05 0.01838882 
 
99 
285704 NM_003789.2 TRADD 3.34473593131219e-05 0.01838882 
197259 NM_006452.3 PAICS 3.36349007470087e-05 0.01838882 
8459 NM_012302.2 LPHN2 3.40706988204152e-05 0.01838882 
64423 NM_031449.3 ZMIZ2 4.09208974373448e-05 0.01838882 
9632 NM_001014436.1 DBNL 3.73561750151898e-05 0.01838882 
10482 NM_020877.2 DNAH2 3.71439285544299e-05 0.01838882 
1728 NM_005027.2 PIK3R2 4.04726930276837e-05 0.01838882 
5831 NM_000402.3 G6PD 4.02223146417751e-05 0.01838882 
1861 NM_001042432.1 CLN3 3.90233534257564e-05 0.01838882 
199990 NM_016817.2 OAS2 3.93538992225112e-05 0.01838882 
162989 NM_001025436.1 SPAG16 4.0905715730101e-05 0.01838882 
55902 NM_012343.3 NNT 4.20883197582258e-05 0.01862246 
1201 NM_001008566.1 TPST2 4.28646248396797e-05 0.01867858 
78994 NM_002514.2 NOV 4.57815361453796e-05 0.01880967 
64759 NM_004672.3 MAP3K6 4.57677259130294e-05 0.01880967 
2764 NM_000561.2 GSTM1 4.95803374591224e-05 0.01884134 
5999 NM_014862.3 ARNT2 4.75746050955722e-05 0.01884134 
8717 NM_004457.3 ACSL3 5.05099499300568e-05 0.01886579 
9315 NM_005613.3 RGS4 5.25736354256266e-05 0.01938484 
55196 NM_021922.2 FANCE 5.71839328783817e-05 0.02055762 
2882 NM_178173.2 CCDC36 5.65919122514941e-05 0.02055762 
23654 NM_022753.2 S100PBP 5.83550366744613e-05 0.02067423 
63901 NM_001357.2 DHX9 5.89460007985228e-05 0.02067423 
5329 NM_001008566.1 TPST2 6.24822673614911e-05 0.02099954 
1716 NM_020677.2 NMRAL1 6.62684189673022e-05 0.02106347 
9761 NM_001042470.1 SUMF2 6.66472865906377e-05 0.02106347 
84065 NM_016464.3 TMEM138 6.52029206915914e-05 0.02106347 
7022 NM_001098.2 ACO2 6.46911756015795e-05 0.0210634 
84309 NM_032928.2 TMEM141 6.83972720948762e-05 0.02106809 
22824 NM_014604.2 TAX1BP3 6.87231913095717e-05 0.02106809 
54344 NM_001238.1 CCNE1 6.97302129315534e-05 0.02106809 
57418 NM_201263.2 WARS2 7.32759028540452e-05 0.02163551 
4856 NM_001630.1 ANXA8 7.48097801582648e-05 0.02173261 
541578 NM_003068.3 SNAI2 7.66132426993342e-05 0.02178061 
7057 NM_003564.1 TAGLN2 7.74967930928184e-05 0.02178061 
79447 NM_002622.4 PFDN1 7.76449625104063e-05 0.02178061 
 
100 
898 NM_005949.2 MT1F 8.0881752980737e-05 0.02215389 
84056 NM_003486.5 SLC7A5 8.41466580289125e-05 0.02234789 
1902 NM_001961.3 EEF2 8.40818399245912e-05 0.02234789 
10928 NM_002691.1 POLD1 8.89663907303456e-05 0.02264312 
2944 NM_015143.1 METAP1 8.78974126734235e-05 0.02264312 
84171 NM_017583.3 TRIM44 9.5518669478487e-05 0.02362486 
1200 NM_194272.1 RBPMS2 9.61095121189252e-05 0.02624868 
5414 NM_177938.2 P4HTM 9.55167040563837e-05 0.02362486 
91373 NM_001002913.1 PTRH1 9.94263729602523e-05 0.02397773 
10381 NM_003507.1 FZD7 0.000100371 0.02397773 
23054 NM_002996.3 CX3CL1 0.000102798 0.02419092 
79077 NM_001467.4 SLC37A4 0.000104586 0.02419092 
23636 NM_006066.2 AKR1A1 0.000105141 0.02419092 
7317 NM_006793.2 PRDX3 0.000104887 0.02419092 
84276 NM_030806.3 C1orf21 0.000107566 0.0245524 
5329 NM_002889.2 RARRES2 0.000111236 0.02519007 
101 NM_022746.2 MOSC1 0.000115906 0.02544615 
10352 NM_001014380.1 KATNAL1 0.000118296 0.02558037 
51441 NM_004237.2 TRIP13 0.000122917 0.02580368 
8407 NM_000709.2 BCKDHA 0.000132539 0.02666021 
2178 NM_198723.1 TCEA2 0.00013804 0.02737947 
4814 NM_004772.1 C5orf13 0.000139685 0.02751598 
10447 NM_018199.2 EXD2 0.000141228 0.02763069 
9064 NM_000391.3 TPP1 0.000145732 0.02798407 
593 NM_001010883.1 FAM102B 0.000150389 0.02798407 
26579 NM_198597.1 SEC24C 0.000151222 0.02798407 
132160 NM_001080432.1 FTO 0.000151791 0.02798407 
23016 NM_005853.5 IRX5 0.000150484 0.02798407 
6624 NM_018973.3 DPM3 0.000169968 0.02884993 
1660 NM_152829.1 TES 0.000179043 0.02884993 
23173 NM_005436.2 CCDC6 0.000174379 0.02884993 
81563 NM_014286.2 FREQ 0.000178277 0.02884993 
7965 NM_007111.3 TFDP1 0.000166887 0.02884993 
54872 NM_138809.3 CMBL 0.000175685 0.02884993 
9140 NM_023015.3 INTS3 0.000171804 0.02884993 
28231 NM_014758.1 SNX19 0.000161444 0.02884993 
 
101 
57007 NM_015509.2 NECAP1 0.00016098 0.02884993 
83648 NM_007326.2 CYB5R3 0.000173803 0.02884993 
55054 NM_001398.2 ECH1 0.000174269 0.02884993 
30834 NM_017727.4 TMEM214 0.000170541 0.02884993 
219541 NM_001012633.1 IL32 0.000164238 0.02884993 
8546 NM_198836.1 ACACA 0.000179516 0.02889931 
54542 NM_006295.2 VARS 0.000184208 0.02910892 
10265 NM_139207.1 NAP1L1 0.00018831 0.02914745 
7172 NM_001033566.1 RHOT1 0.00018658 0.02914745 
284611 NM_016553.3 NUP62 0.000192413 0.02950571 
1891 NM_002395.3 ME1 0.000192875 0.02950571 
821 NM_003246.2 THBS1 0.000201034 0.03011315 
8714 NM_000308.2 CTSA 0.000200184 0.03011315 
25842 NM_000600.1 IL6 0.000207829 0.03034092 
55081 NM_147157.1 SIGMAR1 0.000206006 0.03034092 
5159 NM_002931.3 RING1 0.000205774 0.03034092 
25915 NM_006452.3 PAICS 0.000215134 0.03051396 
1453 NM_000903.2 NQO1 0.000213398 0.03051396 
30851 NM_005180.5 BMI1 0.000212535 0.03051396 
79068 NM_005189.1 CBX2 0.00021538 0.03051396 
115290 NM_001975.2 ENO2 0.000210595 0.03051396 
51110 NM_024545.2 SAP130 0.000213278 0.03051396 
2071 NM_001953.2 ECGF1 0.000216948 0.03058540 
9915 NM_020311.2 CXCR7 0.000218389 0.03063840 
8140 NM_015945.10 SLC35C2 0.000220518 0.03078689 
6376 NM_153824.1 PYCR1 0.00022272 0.03082657 
55633 NM_024907.5 FBXO17 0.000226146 0.03097120 
4939 NM_080597.2 OSBPL1A 0.000229904 0.03120604 
2648 NM_000113.2 TOR1A 0.000230031 0.03120604 
5480 NM_012280.2 FTSJ1 0.00023574 0.01534365 
7546 NM_173659.2 RPUSD3 0.000238813 0.03179745 
9887 NM_006745.3 SC4MOL 0.000254466 0.03264302 
9419 NM_080918.1 DGUOK 0.000253976 0.03264302 
26136 NM_000127.2 EXT1 0.000250206 0.03264302 
5476 NM_001382.2 DPAGT1 0.000253379 0.03264302 
37 NM_000532.3 PCCB 0.000248994 0.03264302 
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1915 NM_024031.2 PRR14 0.000252986 0.03264302 
29894 NM_001033714.1 NOP2 0.000254033 0.03264302 
7035 NM_001098209.1 CTNNB1 0.000254368 0.03264302 
8459 NM_018677.2 ACSS2 0.000259204 0.03266266 
64757 NM_002885.1 RAP1GAP 0.000260075 0.0326626 
9166 NM_004613.2 TGM2 0.000261711 0.03272521 
8563 NM_138768.2 MYEOV 0.000263259 0.03277636 
25977 NM_005510.3 DOM3Z 0.00026804 0.03296090 
56935 NM_001024943.1 ASL 0.00026979 0.03296090 
29128 NM_006827.5 TMED10 0.000280801 0.03311049 
11120 NM_004104.4 FASN 0.000272866 0.03311049 
57407 NM_031266.2 HNRNPAB 0.000281387 0.03311049 
1938 NM_007111.3 TFDP1 0.000277765 0.03311049 
10309 NM_080927.3 DCBLD2 0.000281675 0.03311049 
51026 NM_021976.3 RXRB 0.000276902 0.03311049 
80023 NM_001037984.1 SLC38A10 0.000283212 0.03311049 
124565 NM_022748.10 TNS3 0.000297471 0.03381531 
55450 NM_005914.2 MCM4 0.000297051 0.03381531 
6856 NM_005984.1 SLC25A1 0.000298726 0.03382429 
9123 NM_182776.1 MCM7 0.000304556 0.03394978 
8324 NM_017857.2 SSH3 0.000304225 0.03394978 
340526 NM_014313.2 TMEM50A 0.000304416 0.03394978 
2026 NM_080415.1 SEPT4 0.000302094 0.03394978 
648 NM_002333.1 LRP3 0.000309031 0.03431560 
10538 NM_001070.3 TUBG1 0.000310619 0.03435925 
3429 NM_001017369.1 SC4MOL 0.000316433 0.03438257 
9270 NM_022842.3 CDCP1 0.000316626 0.03438257 
10935 NM_002388.3 MCM3 0.000316509 0.03438257 
10327 NM_001402.5 EEF1A1 0.000327241 0.03467315 
6274 NM_003677.3 DENR 0.000327809 0.03467315 
10972 NM_002576.3 PAK1 0.000327158 0.03467315 
4173 NM_001033859.1 ACADVL 0.000327924 0.03467315 
25907 NM_021078.2 KAT2A 0.000325163 0.03467315 
118429 NM_014388.5 C1orf107 0.000336112 0.03471458 
91966 NM_005505.3 SCARB1 0.000335411 0.03471458 
6015 NM_001078173.1 FAM127C 0.000333045 0.03471458 
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64689 NM_058219.2 EXOSC6 0.000355071 0.03509220 
4302 NM_004140.3 LLGL1 0.000345874 0.03509220 
153129 NM_016072.3 GOLT1B 0.000354646 0.03509220 
85236 NM_003809.2 TNFSF12 0.00034953 0.03509220 
55718 NM_001343.2 DAB2 0.000351302 0.03509220 
134147 NM_020750.1 XPO5 0.000350646 0.03509220 
54946 NM_173511.2 FAM117B 0.000348505 0.03509220 
7027 NM_000485.2 APRT 0.000357117 0.03517359 
90550 NM_001012614.1 CTBP1 0.000367351 0.03597785 
83637 NM_001070.3 TUBG1 0.000373711 0.03643367 
1601 NM_006430.2 CCT4 0.000384073 0.03719170 
84619 NM_030782.3 CLPTM1L 0.000387018 0.03735110 
154 NM_015252.2 EHBP1 0.000404959 0.03818568 
157567 NM_003335.2 UBA7 0.000412487 0.03872297 
4893 NM_001048197.1 SNHG3-
RCC1 
0.000415366 0.03872297 
2348 NM_003489.2 NRIP1 0.000416043 0.03872297 
9677 NM_001005245.1 OR5M11 0.000421566 0.03911045 
4034 NM_016724.1 FOLR1 0.000426705 0.03933859 
4199 NM_053275.3 RPLP0 0.000429611 0.03947481 
23530 NM_004462.3 FDFT1 0.000441287 0.03964234 
1140 NM_138387.2 G6PC3 0.000433172 0.03964234 
79109 NM_144641.1 PPM1M 0.000436942 0.03964234 
23301 NM_001806.2 CEBPG 0.000443599 0.03964234 
64855 NM_152341.2 PAQR4 0.000449277 0.03988027 
10575 NM_022168.2 IFIH1 0.000456335 0.04025829 
10295 NM_014564.2 LHX3 0.000455799 0.04025829 
1123 NM_057159.2 LPAR1 0.000463767 0.04033545 
84733 NM_015899.1 PLEKHA9 0.000474145 0.04095017 
31 NM_014223.2 NFYC 0.000481775 0.04102250 
3569 NM_001025201.1 CHN1 0.000488202 0.04102250 
5909 NM_024100.3 WDR18 0.000480052 0.04102250 
3996 NM_024407.3 NDUFS7 0.000489246 0.04102250 
8970 NM_002609.3 PDGFRB 0.000478792 0.04102250 
587 NM_144732.2 HNRNPUL1 0.000487434 0.04102250 
3421 NM_018010.2 IFT57 0.000483905 0.04102250 
 
104 
51318 NM_153450.1 MED19 0.000493951 0.04129661 
1755 NM_024336.1 IRX3 0.000525015 0.04151911 
3054 NM_001190.2 BCAT2 0.000525378 0.04151911 
83787 NM_017823.3 DUSP23 0.000514068 0.04151911 
29083 NM_032316.3 NICN1 0.000525485 0.04151911 
5201 NM_015696.3 GPX7 0.000507163 0.04151911 
4750 NM_005881.1 BCKDK 0.000508227 0.04151911 
9319 NM_020179.1 C11orf75 0.000512384 0.04151911 
7407 NM_024516.2 C16orf53 0.000509929 0.04151911 
64853 NM_022074.2 FAM111A 0.000500617 0.04151911 
8634 NM_007129.2 ZIC2 0.000501788 0.04151911 
353091 NM_016644.1 PRR16 0.00051434 0.04151911 
131566 NM_012401.2 PLXNB2 0.000518662 0.04151911 
5058 NM_006337.3 MCRS1 0.000521446 0.04151911 
27042 NM_004937.2 CTNS 0.000523422 0.04151911 
25886 NM_177414.1 PPAP2B 0.000511873 0.04151911 
51054 NM_003334.3 UBA1 0.000510792 0.04151911 
64866 NM_003664.3 AP3B1 0.000529745 0.04164349 
6307 NM_013265.2 C11orf2 0.000529956 0.04164349 
55818 NM_003504.3 CDC45L 0.000539514 0.04180227 
348093 NM_000234.1 LIG1 0.000536005 0.04180227 
1890 NM_024958.1 NRSN2 0.000547103 0.04180227 
6576 NM_001024463.2 HISPPD2A 0.000535383 0.04180227 
6175 NM_004526.2 MCM2 0.000542826 0.04180227 
79595 NM_025230.3 WDR23 0.000552843 0.04195189 
65249 NM_024096.1 DCTPP1 0.000564698 0.04202581 
22884 NM_153741.1 DPM3 0.000565599 0.04202581 
6591 NM_145792.1 MGST1 0.000558806 0.04202581 
2542 NM_005915.4 MCM6 0.000561352 0.04202581 
5532 NM_001007.3 RPS4X 0.000562572 0.04202581 
994 NM_002345.3 LUM 0.000570498 0.04208729 
79582 NM_001093771.1 TXNRD1 0.000570725 0.04208729 
51524 NM_000389.2 CDKN1A 0.000572351 0.04209925 
57472 NM_018988.2 GFOD1 0.000574223 0.04212919 
399979 NM_152766.2 C17orf61 0.000587185 0.04221862 
4839 NM_001037582.1 SCD5 0.000579978 0.04221862 
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54935 NM_003348.3 UBE2N 0.000585709 0.04221862 
7052 NM_005168.3 RND3 0.000600777 0.04234891 
23585 NM_015171.2 XPO6 0.000597791 0.04234891 
353 NM_003574.4 VAPA 0.000593731 0.04234891 
81603 NM_032530.1 ZNF594 0.000599992 0.04234891 
81037 NM_006674.2 HCP5 0.000591838 0.04234891 
1054 NM_000992.2 RPL29 0.000599269 0.04234891 
8022 NM_173510.1 CCDC117 0.000597381 0.04234891 
50 NM_001204.5 BMPR2 0.000619189 0.04242349 
997 NM_001436.2 FBL 0.000614541 0.04242349 
2194 NM_001040437.1 C6orf48 0.000616914 0.04242349 
7318 NM_147148.1 GSTM4 0.00061806 0.04242349 
51185 NM_152409.2 C5orf24 0.000620143 0.04242349 
54765 NM_017815.1 HAUS4 0.000634662 0.04278651 
285367 NM_016223.3 PACSIN3 0.000632239 0.04278651 
8728 NM_014899.3 RHOBTB3 0.000630768 0.04278651 
2720 NM_148912.2 ABHD11 0.000633438 0.04278651 
26061 NM_003469.3 SCG2 0.00064372 0.04283856 
79693 NM_032493.2 AP1M1 0.00064943 0.04283856 
9587 NM_018054.4 ARHGAP17 0.000639125 0.04283856 
689 NM_017771.3 PXK 0.000640673 0.04283856 
79191 NM_006502.1 POLH 0.000647179 0.04283856 
5096 NM_173462.3 PAPLN 0.000654123 0.04304938 
63908 NM_003025.2 SH3GL1 0.00066475 0.04338434 
6919 NM_000884.2 IMPDH2 0.000667567 0.04338434 
93643 NM_000154.1 GALK1 0.000667511 0.04338434 
51334 NM_005675.3 DGCR6 0.000665923 0.04338434 
146754 NM_020360.2 PLSCR3 0.000679702 0.04362524 
6804 NM_057182.1 CCNE1 0.000681076 0.04362524 
55218 NM_015012.1 TMEM41B 0.000678362 0.04362524 
821 NM_001070.3 TUBG1 0.000681005 0.04362524 
10606 NM_014063.5 DBNL 0.00068331 0.04367107 
64766 NM_003164.3 STX5 0.000685873 0.04373769 
138428 NM_003068.3 SNAI2 0.000699122 0.04399723 
8562 NM_022075.3 LASS2 0.00069906 0.04399723 
4802 NM_018353.3 C14orf106 0.000703016 0.04403466 
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5919 NM_080927.3 DCBLD2 0.000712664 0.04436409 
23413 NM_001127218.1 POLD2 0.000716696 0.04439446 
94241 NM_017741.3 DCAF16 0.000717783 0.04439446 
6257 NM_017481.2 UBQLN3 0.0007218 0.04454715 
50861 NM_033290.2 MID1 0.000738139 0.04461884 
65123 NM_004463.2 FGD1 0.000728951 0.04461884 
4673 NM_032827.4 ATOH8 0.000743706 0.04461884 
2131 NM_014972.1 TCF25 0.000742752 0.04461884 
134492 NM_003377.3 VEGFB 0.000742445 0.04461884 
1797 NM_002388.3 MCM3 0.000744682 0.04461884 
5534 NM_170662.3 CBLB 0.000735678 0.04461884 
3159 NM_199189.1 MATR3 0.000734773 0.04461884 
7283 NM_018330.4 KIAA1598 0.000728324 0.04461884 
51247 NM_194313.2 KIF24 0.000748505 0.04463561 
10658 NM_031455.2 CCDC3 0.00076176 0.04464056 
6307 NM_018101.2 CDCA8 0.000758987 0.04464056 
1798 NM_033212.2 CCDC102A 0.000755786 0.04464056 
4037 NM_002586.4 PBX2 0.000756601 0.04464056 
28988 NM_016147.1 PPME1 0.000774101 0.04485836 
54961 NM_032230.1 C12orf26 0.000776755 0.04485836 
51333 NM_014599.4 MAGED2 0.000776015 0.04485836 
4176 NM_001567.2 INPPL1 0.000784869 0.0449658 
7283 NM_005866.2 SIGMAR1 0.000782114 0.0449658 
5424 NM_001619.3 ADRBK1 0.000788072 0.04505952 
10445 NM_006579.1 EBP 0.000790369 0.04509776 
85014 NM_058182.4 FAM165B 0.00079855 0.04527541 
2539 NM_002205.2 ITGA5 0.000809365 0.04529449 
1839 NM_001128591.1 PSMG4 0.000804531 0.04529449 
26018 NM_207514.1 DEF8 0.000813456 0.04529449 
7052 NM_213618.1 ST5 0.00080303 0.04529449 
150864 NM_080725.1 SRXN1 0.000813534 0.04529449 
1497 NM_030573.2 THAP7 0.000811648 0.04529449 
8613 NM_031407.3 HUWE1 0.000807429 0.04529449 
51090 NM_001017922.1 ERMAP 0.000817153 0.04536933 
26100 NM_018241.2 TMEM184C 0.000823412 0.04544155 
79669 NM_003861.1 WDR22 0.000830385 0.04544155 
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92579 NM_001789.2 CDC25A 0.000831094 0.04544155 
339834 NM_138927.1 SON 0.000842126 0.04595738 
1727 NM_015043.3 TBC1D9B 0.000847783 0.04616984 
219487 NM_000294.1 PHKG2 0.00085244 0.04616984 
8204 NM_012446.2 SSBP2 0.000860389 0.04651276 
1716 NM_021239.1 RBM25 0.000866367 0.04655745 
3182 NM_032937.3 C9orf37 0.000872118 0.04655745 
8742 NM_018482.2 ASAP1 0.000873973 0.04655745 
1487 NM_174940.2 TMEM80 0.000873755 0.04655745 
10482 NM_030793.3 FBXO38 0.000863369 0.04655745 
116092 NM_001040409.1 MTHFD2 0.00086934 0.04655745 
55288 NM_001002027.1 ATP5G1 0.000881402 0.04668348 
54867 NM_003494.2 DYSF 0.000885155 0.04679606 
1021 NM_025205.3 MED28 0.000896396 0.04680077 
4494 NM_019063.2 EML4 0.000902878 0.04681842 
56267 NM_031845.2 MAP2 0.000901844 0.04681842 
90416 NM_006777.3 ZBTB33 0.000899449 0.04681842 
51092 NM_024103.2 SLC25A23 0.000908701 0.04700404 
6774 NM_012280.2 FTSJ1 0.000911338 0.04705578 
29950 NM_015537.3 NELF 0.000914681 0.04705945 
3231 NM_001005753.1 VPS24 0.000920294 0.04726367 
25870 NM_032195.1 SON 0.000922745 0.04730507 
5327 NM_002868.2 RAB5B 0.000935415 0.04737679 
114876 NM_016947.1 C6orf48 0.000935241 0.04737679 
6515 NM_004946.1 DOCK2 0.000932631 0.04737679 
8365 NM_024053.3 CENPM 0.000927474 0.04737679 
11100 NM_007229.1 PACSIN2 0.000933377 0.04737679 
738 NM_004775.2 B4GALT6 0.000935675 0.04737679 
397 NM_014452.3 TNFRSF21 0.000943967 0.04751728 
1499 NM_005412.4 SHMT2 0.000945059 0.04751728 
167227 NM_198580.1 SLC27A1 0.000959337 0.0477304 
10280 NM_024736.5 GSDMD 0.000960528 0.04773044 
54946 NM_005902.3 SMAD3 0.000952393 0.04773044 
2222 NM_080645.2 COL12A1 0.000954068 0.04773044 
949 NM_004117.2 FKBP5 0.000976899 0.04810893 
64135 NM_016016.1 SLC25A39 0.000978788 0.04811956 
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4172 NM_033161.2 SURF4 0.00098456 0.04824391 
57510 NM_080670.2 SLC35A4 0.000986244 0.04824391 
124222 NM_133491.2 SAT2 0.000986407 0.04824391 
23266 NM_032866.3 CGNL1 0.001003289 0.04852492 
54681 NM_144998.2 STRA13 0.001004664 0.04852492 
3484 NM_013401.2 RAB3IL1 0.000999402 0.04852492 
751867 NM_001709.3 BDNF 0.001005305 0.04852492 
374291 NM_001042437.1 ST3GAL5 0.001009551 0.04863432 
435 NM_018026.2 PACS1 0.001018274 0.04889073 
140576 NM_144654.2 C9orf116 0.001024248 0.04909561 
3017 NM_014865.2 NCAPD2 0.001030573 0.04923467 
24140 NM_000097.4 CPOX 0.001030065 0.04923467 
90701 NM_006097.3 MYL9 0.001033735 0.04930382 
56998 NM_001852.3 COL9A2 0.001039877 0.04951469 
94234 NM_004712.3 HGS 0.00104849 0.04984224 
8649 NM_000075.2 CDK4 0.001052013 0.04992720 
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Supplementary figure 1: Overexpression of miR-30c-2-3p in MDA-MB-231 cell 
line. miR-30c-2-3p was overexpressed about 38 fold higher when MDA-MB-231 cells 
were transfected with the same concentration of miRNA to perform whole 
transcriptome analysis (***p≤0.001 compared to control, t test). Data are shown as 
mean±s.d of two biological and three technical replicates. 
 
Supplementary figure 2: Linear regression analysis (Spearman rank correlation) 
between scale normalized miR-30c-2-3p and BCL9 mRNA levels identified 
anticorrelation in breast cancer patients (N = 781) from the METABRIC study [106, 
111]. 
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Supplementary figure 3: Linear regression analysis between miR-30c-2-3p and HIF2α 
mRNA levels identified anticorrelation in breast cancer patients from METABRIC 
study [106, 111].  
Supplementary figure 4: Linear regression analysis between scale normalized miR-
30c-2-3p and miR-30c-5p according to Spearman rank correlation mRNA levels 
identified positive correlation in breast cancer patients from METABRIC study [106]. 
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